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S U M M A R Y
Objectives: To provide a comprehensive review of the prevalence of selected hepatitis B virus (HBV)
seromarkers and to identify variability in seroprevalence across the 14 World Health Organization
(WHO) sub-regions and among special groups and populations.
Methods: Analyses involved 568 papers and 736 population studies. The complete data set included 21,
838, 249 individuals and covered the 14 WHO sub-regions.
Results: Of the 687 studies that assessed hepatitis B surface antigen (HBsAg) seroprevalence, 30% had
low (<2% affected), 36% had intermediate (2–8% affected), and 34% had high (>8% affected) endemicity.
Median HBsAg seroprevalence differed by selected populations and among geographic regions. Overall,
median seroprevalence was highest for ‘other’ populations, followed by patients, then by pregnant
women and children. Median seroprevalence of antibody to hepatitis B core antigen (anti-HBc) followed
a similar endemicity pattern to that of HBsAg across the 14WHO sub-regions. Median seroprevalence of
hepatitis B e antigen (HBeAg) showed considerable variability within each population group, with the
greatest potential for infectivity seen among children.
Conclusions: This population-based review provides a comprehensive assessment of the burden of HBV
throughout the world. Signiﬁcant differences in seroprevalence exist between WHO regions, study
populations, and seromarker testing methods. The results presented in this study will enable health
professionals to track worldwide reported seroprevalence of hepatitis B markers.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis is the name given to liver inﬂammation, which is
usually caused by a viral infection, although it can also be caused
by toxic agents or other diseases, such as autoimmune and
metabolic diseases. The causative agent of viral hepatitis type B is
the hepatitis B virus (HBV). The virus interferes with the normal
functioning of the liver by replicating in hepatocytes. The response
by the immune system to combat and potentially eliminate the
infectious agent causes pathological damage and liver inﬂamma-
tion.1 HBV infection is among themost common causes of hepatitis
and can progress to serious liver diseases, such as chronic hepatic
insufﬁciency, cirrhosis (scarring of the liver), and hepatocellular
carcinoma.1–3 About 25% of adults who are chronically infected
during childhood will die from cirrhosis or liver cancer.4
Susceptibility to HBV is general, with immunity only in those
who have been vaccinated or who have developed antibodies to
hepatitis B surface antigen (anti-HBs) following HBV infection.5
Infection with HBV frequently occurs in children and often leads to
the person becoming a chronic carrier, where the virus is present in
the blood and can be transmitted for many years, even if the* Corresponding author. Tel.: +1 801 422 9788; fax: +1 801 422 0273.
E-mail address: Ray_Merrill@byu.edu (R.M. Merrill).
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virus is transmitted through contact with infected blood or body
ﬂuids.2,6–8 It may spread from an infected mother to her child
during the birth process, between children (especially where
overcrowding is common), from a needle stick, or by sexual
contact. HBV is also an occupational hazard among health
workers.6,7
The course of HBV is variable, and the different clinical
manifestations are inﬂuenced by the infected person’s age and
immune status. HBV occurswhen there is aweak antiviral response,
which is more common at a younger age of infection. Nearly 90% of
HBV infected children during the ﬁrst year of life develop chronic
infections, 30%–50% of children infected in the age range 1–4 years
develop chronic infection, and 90% of healthy adults who are
infectedwill recover and be rid of the viruswithin sixmonths.9 HBV
typically resolves within 3 months, but over 10% of cases become
asymptomatic carriers or experience chronic HBV infection.10
Peoplewho develop chronic HBV are at increased risk of developing
cirrhosis and/or liver cancer.11
Acute hepatitis B has no speciﬁc treatment other than trying to
maintain comfort and proper nutritional balance. Chronic hepatitis
B may be treated with drugs. Drugs licensed for treating persons
with chronic HBV include adefovir dipivoxil,12 alpha-interferon,13
lamivudine,13 pegylated interferon,14 entecavir,15 telbivudine,16
and tenofovir.17ses. Published by Elsevier Ltd. All rights reserved.
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been infectedwithHBV, nearly 350million are chronically infected
with HBV and are carriers of the virus.3,7–9 However, this is likely
an underestimation because high-risk populations may be under-
represented in surveillance studies and because of variability in
testing methods.10,14–16 In particular, estimates based on acute
clinical hepatitis B may represent only part of the global burden
associated with HBV, particularly in highly endemic areas where a
large percentage of the populationmay become carriers while they
are children.
The current study involved a systematic review of relevant
published data documenting seroprevalence of HBV markers of
infection and immunity at the regional and national level in the 14
WHO sub-regions. The prevalence of hepatitis B in various areas
has previously been estimated.17–21 Prevalence estimates in the
current study provide updates to previous estimates of the
prevalence of chronic HBV carriers in different populations
throughout the world. Region-speciﬁc prevalence estimates of
HBV are reported according to special groups and populations. The
focus of this paper is on the identiﬁcation of variability in
prevalence of HBV seromarkers according to the 14 WHO sub-
regions and special groups and populations.
2. Methods
2.1. Literature search
All published English and non-English language studies on
hepatitis B seroprevalence published from January 1990 through
July 2009 were identiﬁed from three electronic databases –
MEDLINE, POPLINE, and BIDS (CAB ABS). A mixture of thesaurus
and free-text terms was used. The search terms used to identify all
relevant published data on MEDLINE and POPLINE are stated
below. The search was carried out using the thesaurus, and any
papers containing the terms below, not only in the title or abstract
but also from the MeSH terms (index terms), were identiﬁed. This
resulted in the identiﬁcation of 3698 papers in total; the
breakdown of the number of papers per search (i.e., hepatitis B
and Europe, hepatitis B seroprevalence) is saved in the search
history. This applies to all searches carried out on any database.
The following search terms were used: Hepatitis-B-Antigens/
Hepatitis-B-Core-Antigens/Hepatitis-B-Surface-Antigens/Hepati-
tis-B-e-Antigens/Hepatitis-B/Hepatitis-B-Antibodies/Hepatitis-B-
Chronic/Africa/Asia, Middle East/Mediterranean/Americas, Eur-
ope, Prevalence/Disease-Transmission-Horizontal/Epidemiology.
2.2. Inclusion and exclusion criteria
All articles published between January 1990 and July 2009
containing data on HBV seroprevalence were considered for
inclusion. Studies were excluded if they were reviews and did not
contain primary data, were non-referenced sources, were letters/
correspondence, or were not relevant and/or did not contain
primary seroprevalence data. Studies were also excluded if they
were studies of occult hepatitis B in which all participants were
seronegative for hepatitis B.
2.3. Quality criteria
Each reviewed paper was assigned a quality score. All papers
were categorized as good, reasonable–good, poor–reasonable, or
poor based on three main criteria: sample size, method of
sampling, and response rate. The main quality criterion when
critically reviewing the papers was the method of sampling. The
sample population must be representative of the source popula-
tion for the results to be valid. Random sampling is the goldstandard of sampling because it ensures that chance alone
determines who is included in the sample, greatly minimizing
the possibility of selection bias. However, selection bias may also
be introduced into the study if those who participate differ in
signiﬁcant ways from those who refuse, therefore high response
rates (>80%) are important in order to minimize selection bias.
Sample size was also factored into the assigned quality score. A
sample size of 150 or more was determined to be adequate.
If the method of sampling was random, the response rate was
greater than 80%, the sample size was at least 150, and measures
had been taken to minimize other forms of bias, the study was
categorized as ‘good.’ If one of these three criteria was not met
or the methods employed in the study were deemed likely to
result in some bias, the study was categorized as ‘reasonable.’ If
two of the criteria were not met, or if the study was based on
small numbers or an unrepresentative study population and
there were serious concerns about bias, it was categorized as
‘poor.’ We found that many of the studies did not report the
response rate. These studies were rated down a degree of quality
and assigned scores of, for example, reasonable–good and poor–
reasonable.
Two people reviewed a random sample of 25% of the studies in
order to ensure consistency in the quality grading assigned to the
studies. There was complete agreement on the quality grading of
papers reviewed by both researchers.
2.4. Classiﬁcation of studies
Hepatitis B prevalence studies were included in this report,
regardless of the study design employed.
2.5. Classiﬁcation of countries
Countries were grouped according to the six WHO regions: The
African Region (AFR), the Region of the Americas (AMR), the
Eastern Mediterranean Region (EMR), the European Region (EUR),
the South-East Asia Region (SEAR), and the Western Paciﬁc Region
(WPR). These regions were further divided into 14 sub-regions
based on level of mortality within each country. Those countries
whose sub-region assignment ends in ‘A’ have the lowestmortality
and those whose sub-region assignment ends in ‘E’ have the
highest mortality. Appendix A in the Supplementary Material lists
the WHO Member States by region and mortality stratum.
2.6. Information abstracted
Serological markers of HBV infection and immunity abstracted
for this study included hepatitis B surface antigen (HBsAg),
antibody to hepatitis B core antigen (anti-HBc), and hepatitis B e
antigen (HBeAg). HBsAg is the surface antigen of the virus and if
present indicates either acute or chronic HBV infection; anti-HBc is
an antibody to the hepatitis B core antigen and indicates acute,
chronic, or resolved HBV infection; and HBeAg is a marker of high
HBV infectivity, correlates with HBV replication, and is primarily
used to assess patients with chronic HBV infection.
Serological prevalence data for these markers represented
several populations. The most frequently identiﬁed populations
included the general population, adults, children, pregnant
women, and blood donors. Classiﬁcations used for the marker
HBsAg were high (>8%), intermediate (2–8%), and low (<2%).8
Several special populations were also identiﬁed, including
patients, children of HBsAg-positive mothers, non-injection drug
users, prison staff, college students, medical/hospital employees,
migrants, street adolescents, and military recruits. HIV-positive
patients were included in the ‘patients’ category. Some speciﬁc
racial/ethnic groups identiﬁed were Baka Pygmies, Bushmen,
Table 1
Median HBsAg seroprevalence and the distribution of study scores within each of
the 14 WHO sub-regions
Endemicity,a %
No. Median (%)b Low, % Medium, % High, % Unknown, %
AFR-D 83 14 5 19 74 2
AFR-E 44 10.7 2 32 61 5
WPR-B 109 9.5 5 33 56 6
EUR-B 52 7.5 2 52 46 0
EUR-C 17 5.1 24 41 29 6
EMR-D 25 4.6 12 44 44 0
SEAR-B 17 4.3 29 47 24 0
SEAR-D 84 3.7 24 57 19 0
EMR-B 42 3 21 60 7 12
AMR-B 89 1.2 51 30 11 8
WPR-A 28 1 50 32 7 11
AMR-D 7 0.9 43 14 0 43
AMR-A 37 0.8 54 19 11 16
EUR-A 102 0.7 72 9 6 13
HBsAg, hepatitis B surface antigen; WHO, World Health Organization.
a Low means <2% affected, intermediate means 2–8% affected, and high means
>8% affected.
b Weighted by study quality scores and expressed as percentages. Kruskal–
Wallis Chi-square =282, p<0.001.
Percentages sum to 100 by row.
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Andamanese, and Aborigines.
HBeAg measures are based on positive cases among HBsAg
individuals. The testing method used for each marker was also
abstracted. Information about vaccination interventions was
included and classiﬁed into the following ﬁve categories: (1) ‘n/c’,
meaning no comment wasmade about vaccination interventions in
the article; (2) ‘prior’, meaning the purpose of the study was to
establish baseline data for a vaccination intervention; (3) ‘post’,
meaning the purpose of the study was to evaluate a vaccination
intervention; (4) ‘recommend’, meaning the article recommended
that vaccination interventions should be a priority based on study
results; and (5) ‘concurrent’, meaning that study results were
partially attributed to ongoing vaccination interventions.
2.7. Data consistency check
There were 279 studies that reported prevalence estimates for
both the serologicalmarkers HBsAg and anti-HBc. The lattermarker
should not exceed the former. However, in seven of the 279 studies
(2.5%), HBsAg had higher prevalence estimates than did anti-HBc.
This situation has been observed previously in non-outbreak
populations when there is a large number of false-positive HBsAg.
We assigned a quality score of poor to these studies.
2.8. Statistical analysis
Data were entered into Excel spreadsheet ﬁles and analyzed in
Excel and Statistical Analysis System (SAS) software, version 9.2
(SAS Institute Inc., Cary, NC, USA, 2007). Seroprevalence scores
reﬂect the percentage of the population affected by the selected
markers of HBV. Because seroprevalence scores were highly
skewed, median scores were reported in this study, and evaluated
using the Kruskal–Wallis test and the Wilcoxon rank-sum test.
Seroprevalence scores were weighted according to the quality
index score (i.e., poor = 1, poor/reasonable = 2, reasonable = 3,
reasonable/good = 4, and good = 5). Regression analysis was used
to evaluate whether there was a trend in median seroprevalence
from 1990 through 2009. Because median seroprevalence did not
signiﬁcantly vary for HBsAg (slope = 0.07, p = 0.362), anti-HBc
(slope = 0.05, p = 0.935), or HBeAg (slope = 0.04, p = 0.948),
analyses were based on data combined over the study period.
3. Results
The literature search identiﬁed 708 studies for review. Of these,
140 were excluded, leaving 568 (of which 99 were non-English)
papers that met the inclusion criteria. Some of the papers assessed
more than one group, resulting in data on 736 populations. A line
listing of selected information for each of the 568 papers is
provided in the Supplementary Material (Appendix B). The
information in this table is grouped byWHO sub-region according
to seroprevalence of HBV markers of infection and immunity. A
brief description of the studies is given in terms of country, source,
year, population studied, sample size, data quality, age range,
markers, testing method, and vaccination. Prevalence estimates
were most frequently reported for HBsAg (n = 687), followed by
anti-HBc (n = 327) and then HBeAg (n = 107). Seroprevalence
studies of HBeAg were less likely to involve adults and more likely
to involve pregnant women. Journal citations for the studies are
shown in the Supplementary Material (Appendix C).
Nearly all the studies represented in this report were based on a
cross-sectional study design (n = 724, 98.4%). A small number of
studies estimated prevalence using either case–control (n = 5,
0.7%) or cohort study (n = 7, 1.0%) designs.The distribution of quality scores for the studies was 9% poor,
14% poor/reasonable, 30% reasonable, 9% reasonable/good, and 38%
good.
Comments on vaccination intervention were found in 54% of
the papers. In 12% of the studies the purpose was to establish
baseline data prior to vaccination intervention; in 16% of the
studies the purpose was to evaluate a vaccination intervention; in
65% of the studies vaccination interventions were recommended
as a priority based on study results; and in 7% of the studies the
results were partially attributed to ongoing vaccination interven-
tions.
3.1. Seroprevalence of HBsAg
Of the 687 studies that assessed HBsAg seroprevalence, 30% had
low (<2% affected), 36% had intermediate (2–8% affected), and 34%
had high (>8% affected) endemicity. HBsAg seroprevalence accord-
ing toendemicity is presented for eachof the14WHOsub-regions in
Table 1. Median HBsAg seroprevalence signiﬁcantly differed among
geographic regions (Kruskal–Wallis Chi-square, p< 0.001). Geo-
graphic regions reﬂecting high endemicity include Africa, high-
mortality developing Eastern Mediterranean, parts of Eastern
Europe, and developing Western Paciﬁc; geographic regions
reﬂecting intermediate endemicity include low-mortality develop-
ing Eastern Mediterranean, parts of Eastern Europe, and South-East
Asia; and geographic regions reﬂecting low endemicity include the
Americas, Western Europe, and developed Western Paciﬁc.
Median seroprevalence estimates of HBsAg are reported
according to selected populations and WHO regions grouped
according to endemicity (Table 2). Overall, median seroprevalence
was highest for ‘other’ populations, followed by patients, and then
by pregnantwomen and children.Within group 1 (high endemicity
areas) there was no signiﬁcant difference among the populations;
in group 2 (intermediate endemicity areas) there was a signiﬁcant
difference among the populations, with median HBsAg seropreva-
lence greatest in the ‘other’ category and patients and children;
and in group 3 (low endemicity areas) there was also a signiﬁcant
difference among the populations, with median seroprevalence of
HBsAg greatest in the ‘other’ category and patients, but among the
lowest in children. Median seroprevalence estimates of HBsAg did
not signiﬁcantly differ among the three age groups for children
overall or within endemicity groups.
Table 2
Median seroprevalence estimates of HBsAg according to selected populations and WHO regions grouped according to endemicity
Endemicity,a % Group 1b Group 2c Group 3d
Median (%)e Low Medium High No. Median (%)e No. Median (%)e No. Median (%)*
General (all ages) 4.3 29 39 32 31 13.6 41 6.7 34 0.9
General (adults) 2.6 44 30 26 27 8.2 16 4.5 31 0.9
Blood/tissue donors 2.6 42 31 27 29 11.1 46 4.4 30 0.3
Pregnant women 4.3 37 35 28 36 9.9 34 5.2 38 0.7
Children 4.1 34 28 38 56 11.1 34 7.4 24 0.4
Patients 5.6 16 48 36 21 14.0 32 7.9 24 2.6
Otherf 7.0 18 38 44 27 10.8 31 16.0 46 3.1
Kruskal–Wallis Chi-square p-value 0.001 0.306 0.002 <0.001
HBsAg, hepatitis B surface antigen; WHO, World Health Organization.
a Low means <2% affected, intermediate means 2–8% affected, and high means >8% affected.
b Group 1: AFR-D, AFR-E, WPR-B.
c Group 2: EMR-B, EMR-D, EUR-B, EUR-C, SEAR-B, SEAR-D.
d Group 3: AMR-A, AMR-B, AMR-D, EUR-A, WPR-A.
e Weighted by study quality scores.
f Studies involving selected groups such as drug users, prison ofﬁcers and staff, college students, migrants, street children, refugees, nursing home residents, military
recruits, female sex workers, healthcare workers, and other special populations.
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populations that involved insufﬁcient numbers to group into large
categories. Seroprevalence of HBsAg is presented for selected
groups and special populations in the Supplementary Material
(Appendix D, Figures 1 and 2, respectively). The highest endemicity
is observed in newborns of HBsAg-positive mothers, family
members of chronic HBsAg patients/individuals, and drug users.
In addition, several special populations display high endemicity,
particularly tribal groups in India and Afghan refugees in Iran.
Seroprevalence of HBsAg for studies involving patients is
presented in the Supplementary Material (Appendix D, Figure 3).
Several types of patient are represented in the ﬁgure. The highest
HBsAg seroprevalence is among the studies involving liver disease
patients.
There were 27 studies that were classiﬁed according to urban–
rural settings (12 urban and 15 rural). Of these studies, 23 provided
seroprevalence data on HBsAg. Fifteen of these studies focused on
the general population, two on pregnant women, two on primary
school children, two on adolescents, and two on college students;
14 of the studies were conducted in AFR, eight were conducted in
WPR, and one was conducted in AMR. Median seroprevalence was
not signiﬁcantly different between urban and rural settings
(Wilcoxon Z = 1.02, p = 0.306).
A high number of studies failed to identify vaccination status,
thereby limiting our evaluation of HBsAg seroprevalence by
vaccination classiﬁcation. The level of studies not commenting
on vaccination status was high across all 14 WHO sub-regions.Table 3
Median seroprevalence estimates of anti-HBc according to selected populations and W
Group 1a
Median (%)d No. Med
General (all ages) 21.4 16 38.2
General (adults) 13.2 20 53.6
Blood/tissue donors 11.0 6 57.4
Pregnant women 25.3 9 56.2
Children 12.8 29 15.6
Patients 38.5 14 77.5
Othere 27.5 9 57.9
Kruskal–Wallis Chi-square p-value 0.001 0.00
anti-HBc, antibody to hepatitis B core antigen; WHO, World Health Organization.
a Group 1: AFR-D, AFR-E, WPR-B.
b Group 2: EMR-B, EMR-D, EUR-B, EUR-C, SEAR-B, SEAR-D.
c Group 3: AMR-A, AMR-B, AMR-D, EUR-A, WPR-A.
d Weighted by study quality scores.
e Studies involving selected groups such as drug users, prison ofﬁcers and staff, coll
recruits, female sex workers, healthcare workers, and other special populations.3.2. Seroprevalence of anti-HBc
Median seroprevalence of anti-HBc, weighted by the study
quality scores, follows a similar pattern to that of HBsAg across the
14 WHO sub-regions (i.e., 56.2% for AFR-E, 50.2% for AFR-D, 41.0%
for WPR-B, 37.8% for EUR-B, 32.4% for SEAR-D, 31% for EMR-D,
29.7% forWPR-A, 25% for SEAR-B, 18.7% for EMR-B, 15% for AMR-A,
14% for EUR-C, 13.9% for AMR-B, 11.6% for AMR-D, and 7% for EUR-
A). Median seroprevalence estimates of anti-HBc are reported
according to selected populations and WHO regions grouped
according to endemicity in Table 3. Patients and those in the ‘other’
populations experienced the highest anti-HBc and blood/tissue
donors had the lowest anti-HBc seroprevalence. Anti-HBc sero-
prevalence was least similar among the endemicity groups for
adults who were blood/tissue donors.
Difference scores between the seroprevalence of anti-HBc and
HBsAg were derived for the 278 studies that collected information
on bothmarkers. Median difference scores weighted by the quality
score were similar among the WHO sub-regions in endemicity
group 1 (Kruskal–Wallis Chi-square = 3.0, p = 0.224) and group 2
(Kruskal–Wallis Chi-square = 7.5, p = 0.184), but not group 3
(Kruskal–Wallis Chi-square = 10.1, p = 0.039). Median difference
scores (anti-HBc seroprevalence subtracted by HBsAg seropreva-
lence) for the three groups were 39, 17.1, and 8.2 (23.6 in WPR-A,
13.1 in AMR-B, 8.2 in AMR-A, 6.8 in EUR-A, and 2.9 in AMR-D),
respectively. In addition, median difference scores weighted by the
quality score were 13.8 in the general adult population, 9.5 inHO regions grouped according to endemicity
Group 2b Group 3c
ian (%)d No. Median (%)d No. Median (%)d
17 31.0 26 8.8
8 16.4 24 7.5
10 18.7 16 5.3
7 28.5 12 7.1
12 15.8 17 3.7
8 28.6 17 19.9
7 68.8 42 19.0
6 0.047 <0.001
ege students, migrants, street children, refugees, nursing home residents, military
Table 4
Median seroprevalence estimates of HBeAg among HBsAg-positive cases according to selected populations and WHO regions grouped according to endemicity
Group 1a Group 2b Group 3c
Median (%)d No. Median (%)d No. Median (%)d No. Median (%)d
General (all ages) 20.0 6 25.0 1 20.0 1 5.7
General (adults) 17.9 6 21.5 0 3 4.3
Blood/tissue donors 16.3 2 16.3 0 0
Pregnant women 14.0 16 15.3 18 12.0 7 16.7
Children 22.9 14 22.9 4 0.0 3 67.0
Patients 26.7 3 27.3 1 26.0 0
Othere 36.6 6 47.8 3 36.6 8 20.0
Kruskal–Wallis Chi-square p-value 0.023 0.233 0.195 0.127
HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; WHO, World Health Organization.
a Group 1: AFR-D, AFR-E, WPR-B.
b Group 2: EMR-B, EMR-D, EUR-B, EUR-C, SEAR-B, SEAR-D.
c Group 3: AMR-A, AMR-B, AMR-D, EUR-A, WPR-A.
d Weighted by study quality scores.
e Studies involving selected groups such as drug users, prison ofﬁcers and staff, college students, migrants, street children, refugees, nursing home residents, military
recruits, female sex workers, healthcare workers, and other special populations.
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30.0 in patients, and 23.3 in the ‘other’ populations (Kruskal–
Wallis Chi-square = 20.4, p = 0.002).
3.3. Seroprevalence of HBeAg
Median seroprevalence of HBeAg among HBsAg-positive cases
is reported according to selected populations and endemicity
groups in Table 4. Small numbers caused differences of HBeAg
seroprevalence among the selected populations to be statistically
insigniﬁcant within endemicity groups, but not overall. HBeAg
seroprevalence across the WHO sub-regions varied considerably
(47.8% for WPR-B, 35.4% for AMR-A, 28.3% for SEAR-B, 22% for
SEAR-D, 20.7% for AMR-B, 16.7% for EUR-A, 16.3% for AFR-D, 15.8%
forWPR-A, 13.9% for EUR-C, 13.8% for EMR-B, 12.3% for AFR-E, 8.9%
for EUR-B, and 0% for EMR-D). The high score for each group came
from the WHO sub-region WPR-B. HBeAg seroprevalence for
selected populations within this sub-region are presented in the
Supplementary Material (Appendix D, Figure 4).
3.4. Testing methods
Several testing methods were identiﬁed in the studies
reviewed. The frequency of their use according to the seropreva-
lence markers is presented in Table 5. The table also presents the
median seroprevalence estimate for the various markers and
testing methods. The frequency of testing method varied
considerably, with the enzyme-linked immunosorbent assay
(ELISA) used most frequently. The percentage of studies using
ELISA was more common when the marker HBsAg was beingTable 5
Number and percentage of studies using speciﬁc testing methods according to seropre
HBsAg HBeAg
No. % Median (%)a No.
ELISA 290 42 3.8 36
EIA 129 19 6.1 31
RPHA 54 8 5.8 2
RIA 48 7 5.6 17
Otherb 86 13 3.9 11
NS 80 12 3.6 9
HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; anti-HBc, antibody to
immunoassay; RPHA, reverse passive hemagglutination; RIA, radioimmunoassay; NS, n
a Median scores are weighted by the study quality scores.
b Other includes the following: counting immunoassay (CIA), counterimmunoelectrop
(IA), latex agglutination (LATEX), microparticle enzyme immunoassay (MEIA), particleevaluated compared with HBeAg and anti-HBc. Reverse passive
hemagglutination (RPHA) was also used more frequently for
evaluating HBeAg compared with the other markers. The median
scores were lowest in the ‘not speciﬁed’ (NS) group for HBsAg and
highest in the NS group for HBeAg and anti-HBc. The high
percentage of NS for each of the seroprevalence markers made it
impossible to evaluate signiﬁcant differences among the testing
methods. A higher percentage of NS by region, as high as 67% in one
region, also made it impossible to evaluate whether the use of
testing methods varied according to region.
4. Discussion
The current study identiﬁed 736 studies from 568 papers on
HBV. Of these studies, seroprevalence estimates for HBsAg, anti-
HBc, and HBeAg were available in 687, 327, and 107 studies,
respectively. The studies represent 21 838 249 individuals. The
review covers 20 years of data. Special populations considered
include the general population (adults, children), blood donors,
pregnant women, patients, and other populations. Descriptive
information is provided on each of these populations, along with
detailed information on those groups in the category designated as
‘other’ populations. Information on vaccination, testing method,
and year of the study also adds to the completeness of this review.
It is interesting to note that our analysis was not able to identify a
signiﬁcant global trend from 1990 to 2009 for HBsAg, HBeAg, or
anti-HBc seroprevalence, despite the mass vaccination efforts that
have been conducted during this time period. However, previous
studies have indicated that a lack of temporal variability in
seroprevalence may be due to decreasing worldwide seropreva-valence marker
Anti-HBc
% Median (%)a No. % Median (%)a
34 18.2 119 37 14.9
29 21.3 71 22 19.3
2 12.3 0 0 0
16 16.7 57 18 26.8
10 16.7 41 13 12.0
9 47.8 36 11 32.7
hepatitis B core antigen; ELISA, enzyme-linked immunosorbent assay; EIA, enzyme
ot speciﬁed or not available.
horesis technique (CIEP), hemagglutination inhibition (HI), immunoenzymatic assay
agglutination (PA), passive hemagglutination (PHA).
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methods.22 That may certainly be the case in regards to the
ﬁndings of this study.
Our estimates of HBsAg seroprevalence fall within the ranges
provided by a 2006 US Centers for Disease Control and Prevention
(CDC) publication.23 Median seroprevalence estimates found in
this study for HBeAg match those of previous studies.24 Previous
studies have neglected to analyze seroprevalence estimates by
population type or by the method employed for seromarker
testing. This study demonstrates that hepatitis B endemicity varies
signiﬁcantly by WHO sub-region and population type. A relatively
high proportion of studies that neglected to state the method
employed for seromarker testing prevented us from accurately
determining if seroprevalence estimates varied according to
testing method. Future research that is able to answer this
question would contribute to the literature. This population-based
review provides a comprehensive assessment of the burden of HBV
throughout the world.
4.1. Limitations
This review is limited by the quality of the studies reviewed. On
the basis of our criteria for establishing study quality (e.g., sample
representation of the source population, sample size, potential
biases), only 38% were identiﬁed as 5, on a scale from 1 (poor) to 5
(good). For one WHO region, only 29% of studies were considered
good and in three WHO regions, only 37–40% of studies were
considered good. To avoid providing poor studies equal represen-
tation to good studies in seroprevalence estimates, these estimates
were weighted by the study’s quality score. There was no way,
other than inter-rater reliability and comparing our ﬁnal estimates
with the literature, to assess the validity of our quality assessment
of the studies that we reviewed. Our strategy for weighting
estimates according to quality score is not perfect, and it is likely
that weighting median seroprevalence estimates by quality score
does not eliminate all the deviations from the true seroprevalence
values that are caused by many of the poorly developed study
designs employed in the lower-quality papers that we reviewed.
Seroprevalence markers were inﬂuenced by the timing of
hepatitis B vaccination. Over the study period, vaccinationAppendix A. Member States by WHO region and mortality stratum
Region and mortality stratum Description Broad groupin
Africa (AFR)
AFR-D Africa with high child and
high adult mortality
High-mortalit
developing
AFR-E Africa with high child and
very high adult mortality
High-mortalit
developing
Americas (AMR)
AMR-A Americas with very low
child and very low adult
mortality
Developed
AMR-B Americas with low child
and low adult mortality
Low-mortality
developing
AMR-D Americas with high child
and high adult mortality
High-mortalit
developinginterventions became widely adopted in many WHO regions.
Unfortunately, the high number of studies with no information
about vaccination limited our ability to evaluate the effect of
vaccination on seroprevalence scores. It would be useful if papers
routinely included the timing of vaccination intervention relative
to their study.
Most studies identiﬁed the testing method used for estimating
seroprevalence. However, there remained 9–12% of studies,
depending on the seroprevalence marker, that did not specify
the testing method used. For certain WHO regions, the percentage
was as high as 67%. Again, routine inclusion of such information in
papers assessing HBV seroprevalence would be useful.
Lastly, while we meant to be as exhaustive as possible in our
review methodology, it is possible that we missed studies that
have been published on hepatitis B seroprevalence over the last 20
years.
5. Conclusions
This study is a comprehensive review of the literature
comprising studies that measured the seroprevalence of three
markers of hepatitis B infection (HBsAg, HBeAg, anti-HBc). While
there has not been a signiﬁcant trend in median worldwide
seroprevalence over the last 20 years, the study found signiﬁcant
differences in seroprevalence between WHO regions, study
populations, and seromarker testing methods. The results pre-
sented in this study will enable health professionals to track
worldwide reported seroprevalence of hepatitis B markers during
the period from 1990 to 2009.
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y Algeria, Angola, Benin, Burkina Faso, Cameroon, Cape Verde, Chad,
Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-
Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Sao
Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo
y Botswana, Burundi, Central African Republic, Congo, Cote d’lvoire,
Democratic Republic of the Congo, Eritrea, Ethiopia, Kenya, Lesotho,
Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland,
Uganda, United Republic of Tanzania, Zambia, Zimbabwe
Canada, Cuba, United States of America
Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Brazil,
Chile, Colombia, Costa Rica, Dominica, Dominican Republic, El
Salvador, Grenada, Guadeloupe,z Guyana, Honduras, Jamaica, Mexico,
Panama, Paraguay, Puerto Rico,z Saint Kitts and Nevis, Saint Lucia, Saint
Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay,
Venezuela (Bolivarian Republic of)
y Bolivia, Ecuador, Guatemala, Haiti, Nicaragua, Peru
Appendix A (Continued )
Region and mortality stratum Description Broad grouping Member States
South-East Asia (SEAR)
SEAR-B South-East Asia with low
child and low adult
mortality
Low-mortality
developing
Indonesia, Sri Lanka, Thailand
SEAR-D South-East Asia with high
child and high adult
mortality
High-mortality
developing
Bangladesh, Bhutan, Democratic People’s Republic of Korea, India,
Maldives, Myanmar, Nepal, Timor-Leste
EURope (EUR)
EUR-A Europe with very low child
and very low adult mortality
Developed Andorra, Austria, Belgium. Croatia, Cyprus, Czech Republic, Denmark,
Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy,
Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San
Marino, Slovenia, Spain, Sweden, Switzerland, United Kingdom
EUR-B Europe with low child
and low adult mortality
Developed Albania, Armenia, Azerbaijan, Bosnia and Herzegovina, Bulgaria,
Georgia, Greenland,z Kyrgyzstan, Poland, Romania, Slovakia, Tajikistan,
The former Yugoslav Republic of Macedonia, Serbia and Montenegro,
Turkey, Turkmenistan, Uzbekistan
EUR-C Europe with low child
and high adult mortality
Developed Belarus, Estonia, Hungary, Kazakhstan, Latvia, Lithuania, Republic of
Moldova, Russian Federation, Ukraine
Eastern Mediterranean
(EMR)
EMR-B Eastern Mediterranean with
low child and high adult
mortality
Low-mortality
developing
Bahrain, Iran (Islamic Republic of), Jordan, Kuwait, Lebanon, Libyan
Arab Jamahiriya, Oman, Qatar, Saudi Arabia, Syrian Arab Republic,
Tunisia, United Arab Emirates, West Bank and Gaza Stripz
EMR-D Eastern Mediterranean with
high child and high adult
mortality
High-mortality
developing
Afghanistan, Djibouti, Egypt,* Iraq, Morocco, Pakistan, Somalia, Sudan,
Yemen
Western Paciﬁc
(WPR)
WPR-A Western Paciﬁc with very low
child and very low adult
mortality
Developed Australia, Brunei Darussalam, Japan, New Zealand, Singapore
WPR-B Western Paciﬁc with low
child and low adult
mortality
Low-mortality
developing
Cambodia,y China, Cook Islands, Fiji, French Ploynesia,z Kiribati, Lao
People’s Democratic Republic,y Malaysia, Marshall Islands, Micronesia
(Federated States of), Mongolia, Nauru, Niue, Palau, Papua New
Guinea,y Philippines, Republic of Korea, Samoa, Solomon Islands,
Tonga, Tuvalu, Vanuatu, Viet Nam
* Following improvements in child mortality over recent years, Egypt meets criteria for inclusion in subregion EMRO-B with low child mortality and low adult mortality.
Egypt has been included in EMR-D for presentation of subregional totals for mortality and burden to ensure comparability with previous editions of The World Health Report
and other WHO publications.
y Although Cambodia, the Lao People’s Democratic Republic, and Papua New Guinea meet criteria for high child mortality, they have been included in the WPRO-B
subregion with other developing countries of the Western Paciﬁc Region for reporting purposes.
z These countries are not member states of the World Health Organization.
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Appendix B. Summary information from studies on HBV prevalence estimates according to WHO region
Country Source Source
Year
Population studied Study
designa
Sample
size
Study quality Age range HBsAg
preva-
lence (%)
Testing
Method
Used
HBeAg
preva-
lenceb (%)
Testing
Method
Used
Anti-HBc
preva-
lencec (%)
Testing
Method
Used
Vaccination
Interventiond
WHO AFR-D Region
1 Algeriae Ayed 1995 Blood donors xxs 1112 Reasonable 18-61 3.6 ELISA 13.0 ELISA Recommend
1 Algeriae Ayed 1995 Pregnant women xxs 515 Reasonable 18-40 1.6 ELISA 11.1 ELISA Recommend
2 Burkina Fasoe Dao 2001 Pregnant women xxs 917 Good 15-45 10.7 ELISA 18.2 ELISA Recommend
3 Cameroone Zekeng 1990 Blood donors xxs 5980 Good 18-45 11.72 ELISA 16.26 ELISA Recommend
4 Cameroon Chiaramonte 1991 Primary school - urban xxs 702 Good 4-14 4.1 ELISA Recommend
5 Cameroon Rapicetta 1991 Primary school xxs 702 Good 4-14 23.2 ELISA n/c
6 Cameroon Ndumbe 1992 Pregnant women xxs 150 Good Unknown 25.3 EIA 5.2 EIA Recommend
7 Cameroon Ndumbe 1993 Baka Pygmies xxs 141 Good 18-45 14.2 EIA 10 EIA 93.6 EIA Recommend
8 Cameroon Ndumbe 1994 Pregnant women - rural xxs 369 Good 10-49 5.4 ELISA 84.6 ELISA n/c
9 Cameroon Kowo 1995 Pygmy and Bantu xxs 166 Good 12-80 7.2 MEIA n/c
10 Equatorial Guinea Basaras 1999 Mostly rural pops xxs 2042 Reasonable 1-97 8.8 ELISA Recommend
11 Gabon Richard-
Lenoble
1995 General pop xxs 303 Reasonable 2-80 19 EIA 78 EIA n/c
12 Gabon Bertherat 1998 General pop xxs 442 Good 14-55 13.8 EIA n/c
13 Gabon Bertherat 1999 General urban pop xxs 442 Reasonable Unknown 13.6 EIA n/c
13 Gabon Bertherat 1999 General rural pop xxs 211 Reasonable Unknown 19.4 EIA n/c
14 Gabon Makuwa 2008 Pregnant women xxs 1186 Poor-Reason 14-40 9.2 EIA 10.1 EIA n/c
15 Gabon Makuwa 2009 General urban pop xxs 394 Poor-Reason 14-60 12.9 EIA n/c
15 Gabon Makuwa 2009 General rural pop xxs 961 Poor-Reason 15-60+ 7.6 EIA n/c
16 Gambia Whittle 1990 Children from Manduar xxs 115 Good .5-4 38.2 RPHA 32.2 RIA Post
16 Gambia Whittle 1990 Children from Manduar xxs 105 Good 5-9 32.4 RPHA 22.9 RIA Post
16 Gambia Whittle 1990 Children from Manduar xxs 56 Good 10-14 35.3 RPHA 19.6 RIA Post
16 Gambia Whittle 1990 Children from Manduar xxs 30 Good 15-19 33.3 RPHA 16.7 RIA Post
16 Gambia Whittle 1990 Children from Keneba xxs 213 Good .5-4 10.3 RPHA 8.9 RIA Post
16 Gambia Whittle 1990 Children from Keneba xxs 206 Good 5-9 15.5 RPHA 7.6 RIA Post
16 Gambia Whittle 1990 Children from Keneba xxs 136 Good 10-14 14.0 RPHA 5.1 RIA Post
16 Gambia Whittle 1990 Children from Keneba xxs 47 Good 15-19 17.0 RPHA 2.1 RIA Post
17 Gambia Fortuin 1993 Unvaccinated children xxs 816 Good 3-4 13 RPHA 29 RIA Post
17 Gambia Fortuin 1993 Vaccinated children xxs 720 Good 3-4 1 RPHA 5 RIA Post
18 Ghana Acquaye 1994 Pregnant women xxs 692 Good 13-51 6.4 LATEX Recommend
19 Ghana Adu-Sarkodie 1996 Blood donors xxs 731 Good Unknown 19.5 EIA Recommend
19 Ghana Adu-Sarkodie 1996 Pregnant women xxs 1020 Good Unknown 14 EIA Recommend
20 Ghana Martinson 1996 School children - rural xxs 803 Good 6-18 15.8 RIA 54.8 RIA Prior
21 Ghana Martinson 1998 General pop xxs 1385 Good 1-45+ 20.9 RIA 69.2 RIA Recommend
22 Ghana Adjei 2006 Prison inmates xxs 281 Poor 17-84 17.4 ELISA Recommend
22 Ghana Adjei 2006 Prison ofﬁcers xxs 82 Poor 17-84 3.7 ELISA Recommend
23 Guineae Ivanov 1990 General pop Xxs 1119 Good 1-85 16.6 EIA n/c
24 Madagascar Boisier 1996 General pop xxs 921 Good 1-94 20.5 ELISA 33 ELISA 38.2 ELISA Prior
25 Madagascare Migliani 2000 General pop xxs 654 Reasonable 2-93 14.2 ELISA 42.7 ELISA Recommend
26 Malie Maiga 1990 Adult women xxs 641 Good 14-47 41.7 IA 6.0 IA 91.0 IA Recommend
27 Mauritaniae Rui 1998 School children xxs 267 Reasonable 6-22 16.8 ELISA 28.9 ELISA 50.2 ELISA Recommend
28 Mauritaniae Lo Baidy 1999 Blood donors xxs 349 Reasonable Unknown 20.3 ELISA Recommend
29 Nigeria Amazigo 1990 Urban dwellers xxs 341 Reasonable 17-48 5.6 RIA 6.7 RIA n/c
29 Nigeria Amazigo 1990 Rural dwellers xxs 351 Reasonable 5-56 8.8 RIA 12.3 RIA n/c
30 Nigeria Obi 1993 Pregnant women xxs 250 Reasonable Unknown 4.4 NS n/c
31 Nigeria Olubuyide 1993 Urban dwellers xxs 89 Poor-Reason 0-52 47 ELISA Recommend
31 Nigeria Olubuyide 1993 Rural dwellers xxs 100 Poor-Reason 0-52 49 ELISA Recommend
32 Nigeria Harry 1994 Male blood donors xxs 287 Good 18-55 22 ELISA 30.2 ELISA 86.8 ELISA Recommend
32 Nigeria Harry 1994 Pregnant women xxs 224 Good 14-40 11.6 ELISA 12.0 ELISA 64.3 ELISA Recommend
33 Nigeria Mutimer 1994 Local control patients xxs 219 Poor-Reason 1-56 5.9 EIA 35.2 EIA Recommend
33 Nigeria Mutimer 1994 Commercial blood donors xxs 104 Poor-Reason Unknown 8.7 EIA 48.1 EIA Recommend
34 Nigeria Bada 1996 Pregnant women xxs 100 Poor-Reason 15-41 16 ELISA Recommend
34 Nigeria Bada 1996 Patients xxs 100 Poor-Reason 15-60 36 ELISA Recommend
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Appendix B (Continued )
Country Source Source
Year
Population studied Study
designa
Sample
size
Study quality Age range HBsAg
preva-
lence (%)
Testing
Method
Used
HBeAg
preva-
lenceb (%)
Testing
Method
Used
Anti-HBc
preva-
lencec (%)
Testing
Method
Used
Vaccination
Interventiond
34 Nigeria Bada 1996 Blood donors xxs 295 Poor-Reason 15-54 21.7 ELISA Recommend
35 Nigeria Akenami 1997 Malnourished children xxs 206 Reasonable 1-3 26 ELISA n/c
35 Nigeria Akenami 1997 Healthy children xxs 200 Reasonable 1-3 20 ELISA n/c
36 Nigeria Chikwem 1997 Blood donors xxs 364 Reasonable 20+ 14.8 ELISA n/c
37 Nigeria Halim 1998 Blood donors-males xxs 200 Reasonable 20-54 26 ELISA Recommend
38 Nigeria Aganga-Wil-
liams
1999 Women xxs 501 Reasonable 18-35 8.9 ELISA Prior
39 Nigeria Salako 2002 Chronic renal
failure patients
xxs 45 Poor 17-62 13.3 ELISA Recommend
39 Nigeria Salako 2002 Matched controls xxs 45 Poor 18-66 11 ELISA Recommend
40 Nigeria Oronsaye 2004 Blood donors xxs 5737 Good Unknown 11.0 LATEX n/c
41 Nigeria Akani 2005 Pregnant women xxs 600 Reas-Good Unknown 4.3 ELISA Recommend
42 Nigeria Odusanya 2005 Vaccinated children ccs 223 Reasonable 1-4 1.3 IA Post
42 Nigeria Odusanya 2005 Unvaccinated children ccs 219 Reasonable 1-4 4.6 IA Post
43 Nigeria Uneke 2005 Blood donors xxs 175 Poor-Reason 20-40 14.3 ELISA n/c
43 Nigeria Uneke 2005 HIV patients xxs 490 Poor-Reason 17-60 25.9 ELISA n/c
44 Nigeria Ikeme 2006 Pregnant women xxs 7581 Poor-Reason Unknown 0.84 ELISA n/c
45 Nigeria Lesi 2007 HIV/AIDS patients xxs 120 Reasonable Unknown 9.2 IA 27.3 IA n/c
46 Nigeria Forbi 2008 Female sex workers xxs 720 Poor-Reason 16-36+ 17.1 ELISA n/c
47 Nigeria Okpalugo 2008 Preoperative patients xxs 100 Poor Unknown 18.0 Unknown n/c
48 Nigeria Ola 2008 Butchers xxs 180 Reasonable Unknown 9.4 ELISA Recommend
48 Nigeria Ola 2008 Traders xxs 180 Reasonable Unknown 3.3 ELISA Recommend
49 Nigeria Otegbayo 2008 HIV-infected patients xxs 1779 Reasonable 15-65+ 11.9 ELISA n/c
50 Reunion Islande Michault 2000 Pregnant women xxs 1416 Reasonable 14-45 6.35 EIA n/c
51 Senegal Roingeard 1993 Pregnant women xxs 284 Reasonable Unknown 13.7 ELISA 10.2 ELISA 80 ELISA Concurrent
51 Senegal Roingeard 1993 Newborns xxs 156 Reasonable Unknown 7 ELISA Concurrent
52 Senegal Coursaget 1994 Immunized
children (<3 doses)
cos 63 Reasonable 9-12 12.7 RIA 41.3 RIA Post
52 Senegal Coursaget 1994 Immunized children
(3+ doses)
cos 41 Reasonable 9-12 2.4 RIA 26.8 RIA Post
52 Senegal Coursaget 1994 Immunized children
(w/booster)
cos 51 Reasonable 9-12 2.0 RIA 13.7 RIA Post
52 Senegal Coursaget 1994 Unimmunized children cos 48 Reasonable 9-12 18.7 RIA 72.9 RIA Post
53 Senegal Diop-Ndiaye 2008 HIV-1 patients xxs 363 Reasonable 16-66 16.8 ELISA 83.2 ELISA Recommend
54 Seychelles Bovet 1999 General adult pop xxs 1006 Good 25-64 8 ELISA Concurrent
55 Sierra Leone Hodges 1998 Primary school children xxs 66 Reasonable 6-12 18 ELISA 71 ELISA Recommend
WHO AFR-E Region
1 Burundi de Lalla 1990 Blood donors and
patients
xxs 90 Poor-Reason 15-61 15.6 RIA n/c
2 Central African Rep. Pawlotsky 1995 Patients xxs 157 Good 15-58 14 EIA 4.5 EIA 89 EIA n/c
3 Congoe Itoua-Nga-
poro
1995 Pregnant women xxs 292 Good 15-45 6.5 RIA 2.05 RIA 51.3 RIA Recommend
4 Dem. Rep of Congo Jager 1990 Blood donors xxs 2237 Good Unknown 13.1 NS 70.9 NS n/c
5 Ethiopia Tsega 1995 Blood donors xxs 459 Reas-Good Unknown 11 RIA n/c
6 Ethiopia Rahlenbeck 1997 Blood donors - male xxs 549 Reas-Good Unknown 14.4 LATEX n/c
7 Ethiopia Shimelis 2008 HIV VCT and ART patients xxs 620 Reas-Good <20-50+ 5.7 ELISA 44.8 ELISA n/c
8 Ivory Coaste Lohoues 1998 Pregnant women xxs 395 Reasonable Unknown 18.2 ELISA 15.3 ELISA Prior
8 Ivory Coaste Lohoues 1998 Newborns of
HBsAg+ mothers
xxs 61 Reasonable Unknown 32.8 ELISA Prior
9 Ivory Coast Rouet 2004 HIV positive
pregnant women
xxs 499 Good Unknown 9.0 EIA Recommend
9 Ivory Coast Rouet 2004 HIV negative
pregnant women
xxs 498 Good Unknown 8.0 EIA Recommend
10 Ivory Coastc Kra 2007 Blood donors xxs 1231 Good 18-65 12.5 ELISA n/c
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11 Ivory Coast Rouet 2008 Children infected w/HIV1 xxs 280 Reasonable Unknown 12.1 EIA 82.4 EIA Recommend
12 Kenya Okoth 1991 Outpatients xxs 6748 Reasonable 1-71 3 RPHA Recommend
12 Kenya Okoth 1991 Primary school children xxs 2296 Reasonable Unknown 1.4 RPHA Recommend
13 Kenyae Yamanaka 1991 Pop of Maragua xxs 8210 Reasonable Unknown 3.9 ELISA Recommend
14 Kenya Mwangi 1999 Blood donors xxs 1703 Good 18-60 2.8 RPHA 39.2 EIA n/c
15 Malawi Ahmed 1998 Pregnant women - rural xxs 150 Reasonable Unknown 13 ELISA 17 ELISA 71.7 ELISA n/c
16 Malawi Nyirenda 2008 Hospital patients xxs 226 Good 14-80 17.5 IA Recommend
17 Nambia Joubert 1991 Male pop xxs 475 Reasonable 0-75 12.2 RIA n/c
18 Nambia Joubert 1991 Female pop xxs 420 Reasonable 0-75 10.9 RIA n/c
19 Namibia Aspinall 1994 Children xxs 248 Poor-Reason 5-19 2.4 RIA 2.8 RIA Prior
20 Namibia Steele 1995 Bushmen adults & child xxs 106 Poor-Reason Unknown 5.7 MEIA 19 MEIA Recommend
21 South Africa Klugman 1991 Pregnant women xxs 42 Poor Unknown 9.5 EIA 31 EIA n/c
22 South Africa Gaobepe 1995 Bushmen xxs 400 Good 1-87 6.8 EIA 49.6 EIA Prior
23 South Africa Vardas 1999 Children xxs 2288 Good 0-6 10.4 EIA Prior
24 South Africa Mphahlele 2006 HIV positive patients ccs 167 Reasonable 15-78 16.2 MEIA 85.0 IA n/c
24 South Africa Mphahlele 2006 HIV negative patients ccs 128 Reasonable 15-78 35.2 MEIA 82.0 IA n/c
25 South Africa Firnhaber 2008 HIV patients xxs 502 Reasonable Unknown 4.8 MEIA 42.6 MEIA Recommend
26 Tanzania Jacobs 1994 Voluntary blood donors xxs 525 Good 15-24 10.1 ELISA n/c
26 Tanzania Jacobs 1994 Relative blood donors xxs 529 Good 15-24 13 ELISA n/c
26 Tanzania Jacobs 1994 Relative blood donors xxs 1291 Good 25+ 11.1 ELISA n/c
27 Tanzania Pellizer 1994 General pop xxs 1004 Reasonable 1-76 4.4 ELISA 10 ELISA Prior
28 Tanzania Jacobs 1997 Voluntary blood donors xxs 253 Good 15-24 9.9 ELISA Recommend
28 Tanzania Jacobs 1997 Relative blood donors xxs 952 Good 15-25+ 11.2 ELISA Recommend
29 Tanzania Miller 1998 Healthy adults xxs 403 Good Unknown 6 ELISA 60 ELISA Recommend
30 Tanzania Matee 1999 Blood donors xxs 100 Good 18-60 11 RPHA n/c
31 Tanzania Menendez 1999 Pregnant women xxs 980 Good 15-50 6.3 ELISA 19.3 ELISA 56.2 ELISA Recommend
32 Tanzania Stark 2000 Females - Rural xxs 799 Good 15-45 17 NS 74 NS Recommend
1 Uganda de Lalla 1990 General adult pop xxs 358 Poor-Reason 14-60 10 RIA n/c
33 Zambia Oshitani 1995 Pregnant women xxs 2098 Poor-Reason Unknown 6.5 ELISA 16.1 ELISA Prior
34 Zambia Oshitani 1996 Pregnant women xxs 1861 Good 11-48 5.7 ELISA 12.3 RPHA n/c
35 Zimbabwe Tswana 1996 General pop xxs 3394 Good 10-61 15.4 ELISA 25 ELISA Recommend
36 Zimbabwe Madzime 1999 Pregnant women xxs 984 Good Unknown 25 EIA 3.3 EIA Recommend
WHO AMR-A Region
1 Canada Louie 1992 Hospital patients xxs 3000 Poor 14-99 2.1 EIA n/c
2 Canada Sweet 1993 Pregnant women xxs 5754 Reas-Good Unknown .1 EIA n/c
3 Canada Glasgow 1997 Young adults xxs 661 Poor-Reason 14-30 0.36 EIA Concurrent
4 Canada Roy 1999 Street adolescents xxs 434 Reasonable 14-25 1.6 EIA Recommend
5 USA (Philadelphia) Silverman 1991 Pregnant women- Group I xxs 1555 Reasonable Unknown .8 EIA Prior
5 USA (Philadelphia) Silverman 1991 Pregnant women- Group II xxs 208 Reasonable Unknown 6.7 EIA Prior
6 USA Hyams 1992 Military recruit pop xxs 1538 Reasonable 17-35 .3 EIA 2.3 EIA n/c
7 USA (California) Rhee 1992 Patients xxs 2209 Reasonable 12+ 2.6 NS n/c
8 USA (Alaska) McMahon 1993 Alaska Natives xxs 52022 Good 0-60+ 3.1 EIA 35.4 EIA 8.7 EIA Post
9 USA Morris 1993 Pregnant women xxs 716 Reas-Good Unknown .3 NS n/c
10 USA (Hawaii) Pon 1993 Children xxs 4936 Reasonable 6-17 1.7 RIA Prior
11 USA (Maryland) Caplan 1995 Patients xxs 984 Reasonable Unknown 20 ELISA n/c
12 USA (New York) Montecalvo 1995 Patients xxs 1058 Poor-Reason 1-96 1.4 ELISA 12.8 ELISA Recommend
13 USA (San Francisco) Siegal 1995 General unmarried adults xxs 1108 Reasonable 20-44 14 RIA Recommend
14 USA (Chicago) Sloan 1995 Patients xxs 994 Reas-Good Unknown 3.1 ELISA 19.8 ELISA n/c
15 USA Kaur 1996 General adults xxs 8650 Reasonable Unknown 2.1 EIA 17.8 EIA Recommend
16 USA (St. Louis) Chien 1999 Nursing home residents xxs 199 Poor 60+ 0 EIA 24.1 EIA Prior
17 USA McQuillan 1999 General pop xxs 19502 Good 6-74 .4 ELISA n/c
18 USA (North Caro-
lina)
Pierce 1999 Females xxs 4356 Good Unknown .2 NS Post
19 USA (Alaska) Harpaz 2000 Alaska Natives xxs 603 Reas-Good 0-30 9 RIA & EIA 19 EIA 16 RIA Post
20 USA (San Francisco) Henandez 2000 Females xxs 1337 Reas-Good 18-29 .75 EIA 8.9 EIA n/c
21 USA Patel 2002 Vietnamese Immigrants xxs 743 Reas-Good Unknown 13.9 NS 41.7 NS Recommend
22 USA Euler 2003 Pregnant women (Asian) xxs 2000 Good Unknown 5.79 NS Recommend
22 USA Euler 2003 Pregnant women (White) xxs 1910 Good Unknown .60 NS Recommend
22 USA Euler 2003 Pregnant women (Black) xxs 1855 Good Unknown .97 NS Recommend
22 USA Euler 2003 Pregnant women (Hispanic) xxs 1732 Good Unknown .14 NS Recommend
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Appendix B (Continued )
Country Source Source
Year
Population studied Study
designa
Sample
size
Study quality Age range HBsAg
preva-
lence (%)
Testing
Method
Used
HBeAg
preva-
lenceb (%)
Testing
Method
Used
Anti-HBc
preva-
lencec (%)
Testing
Method
Used
Vaccination
Interventiond
23 USA (Baltimore) Torbenson 2004 Injection drug users xxs 188 Poor-Reason 17+ .04 IA n/c
24 USA Zou 2004 Tissue donors xxs 10901 Good Unknown .23 NS n/c
25 USA (Seattle) Burt 2007 IV drug users xxs 1445 Reasonable 18-30 27 NS Recommend
26 USA (Alaska) Hammitt 2007 Vaccinated children Cos 37 Poor 13-15 0.0 ELISA Recommend
27 USA (San Francisco) Lin 2007 Asian American pop xxs 3163 Poor-Reason 18-101 8.9 NS Recommend
28 USA (New York) Toussi 2007 HIV positive children xxs 242 Reasonable-Good 0-23 .02 NS 83.5 NS Recommend
29 USA Tsui 2007 HIV positive women xxs 3700 Poor-Reason Unknown 13.2 EIA n/c
30 USA Amesty 2008 Drug users xxs 1211 Poor-Reasonable 15-40 26.8 ELISA Recommend
31 USA (Grand Rapids) Hall 2008 Emergency
department patients
xxs 403 Reasonable 15-49 .74 ELISA n/c
32 USA Hennessey 2009 White jail inmates xxs 1292 Good 15-40+ .9 EIA 19 EIA Recommend
33 USA (Northern
California)
Levy 2009 Immigrants xxs 1512 Reasonable 18-35 4.1 PCR Recommend
WHO AMR-B Region
1 Argentina Silveira 1999 General pop xxs 1454 Reasonable 1-40 .2 EIA 2.1 ELISA Recommend
2 Argentina Bautista 2009 Non-immigrant
female sex workers
xxs 456 Poor-Reasonable Unknown 12.6 ELISA n/c
2 Argentina Bautista 2009 Immigrant
female sex workers
xxs 169 Poor-Reasonable Unknown 19.4 ELISA n/c
3 Belize Craig 1993 Military personnel xxs 492 Reasonable 18-44 4 ELISA 33 ELISA Recommend
4 Belize Chamberlin 1996 School students xxs 587 Reas-Good 4-22 7.7 EIA 43.3 EIA Prior
5 Belize Scott-Wright 1997 Pregnant women xxs 543 Good 14+ .2 ELISA 14.9 ELISA Recommend
6 Brazile Passos 1992 General pop xxs 1951 Reas-Good 1-65 .1 IA 7.69 IA n/c
7 Brazile Sabino 1992 Pregnant women xxs 477 Poor-Reason 14-46 .4 IA 9.2 IA n/c
8 Brazile Goncales Jr. 1993 Blood donors xxs 29833 Good Unknown 1.52 ELISA 11 ELISA n/c
9 Brazil Porto 1994 Street adolescents xxs 496 Reasonable 9-20 2 EIA 13.5 EIA Recommend
10 Brazil (Amazon)e Soares 1994 Pop of Paranatinga xxs 222 Reas-Good Unknown 14.4 EIA Recommend
10 Brazil (Amazon)e Soares 1994 Pop of Maroxewara xxs 128 Reas-Good Unknown 0 EIA Recommend
11 Brazil Vasconcelos 1994 Blood donors xxs 5000 Good 18-65 .8 EIA 13.9 EIA n/c
12 Brazile Uip 1995 Blood donors xxs 2521 Reas-Good 18-60 .67 ELISA 6.66 ELISA n/c
13 Brazil e Azevedo 1996 Indigenous children xxs 222 Poor-Reason 0-14 4.5 IA 44.1 IA Prior
13 Brazile Azevedo 1996 Women of fertile age xxs 33 Poor-Reason Unknown 12 IA Prior
14 Brazile Cardoso 1996 Pregnant women xxs 1459 Reasonable 12-49 .5 ELISA Recommend
15 Brazile Duarte 1996 Pregnant women xxs 7992 Good Unknown .95 ELISA 21.3 EIA Recommend
16 Brazil Souto 1997 General pop xxs 735 Reas-Good 10-90 1.2 EIA Recommend
17 Brazile Clemens 2000 General pop xxs 3653 Good 1-40 7.9 ELISA Recommend
18 Brazile Miranda 2000 Patients xxs 632 Reasonable Unknown .3 ELISA 13.9 ELISA n/c
19 Brazile Reiche 2000 Pregnant women xxs 1502 Reasonable 12-58 .8 ELISA Recommend
20 Brazil Treitinger 2000 Blood donors xxs 2583 Reasonable Unknown .1 EIA 8.6 EIA n/c
21 Brazil Aguiar 2001 Blood donors xxs 552 Reasonable 19-54 .7 EIA 9.4 EIA n/c
22 Brazil Rosini 2003 Blood donors xxs 263795 Good Unknown .64 IA 5.35 IA Recommend
23 Brazil Souza 2003 Hemodialysis patients xxs 100 Reasonable 13-82 4 ELISA 39 ELISA n/c
24 Brazil Ono-Nita 2004 Asian participants xxs 305 Good Unknown 28.4 EIA 59.3 EIA Recommend
24 Brazil Ono-Nita 2004 Western participants xxs 209 Good Unknown 9.9 EIA 26.8 EIA Recommend
25 Brazilc Souza 2004 HIV patients xxs 401 Reasonable 18-65+ 8.5 ELISA 39.7 ELISA n/c
26 Brazil Ciorlia 2005 Healthcare workers xxs 1433 Good Unknown 0.8 ELISA Recommend
26 Brazil Ciorlia 2005 Healthcare admin
personnel
xxs 872 Good Unknown 0.2 ELISA Recommend
26 Brazil Ciorlia 2005 Blood donor candidates xxs 2583 Good Unknown 0.2 ELISA Recommend
27 Brazilc Valente 2005 Blood donors xxs 25891 Good Unknown 0.6 ELISA n/c
28 Brazil Andrade 2006 Blood donors xxs 128497 Good Unknown .27 MEIA 3.68 MEIA Recommend
29 Brazil Batista 2006 Dentists xxs 474 Good 21-69 0.6 ELISA 1.1 ELISA Recommend
30 Brazil Bellissimo-
Rodrigues
2006 Dentists xxs 135 Reasonable 22-56 0.7 ELISA 8.1 ELISA Post
31 Brazil Bertolini 2006 Pregnant women xxs 3188 Poor-Reason 12-44 1.5 ELISA 18.5 ELISA Recommend
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32 Brazil Ferreria 2006 Hemodialysis patients xxs 1095 Good 3-97 2.4 ELISA 27.3 ELISA n/c
33 Brazil Oliveria 2006 Secondary school
students
xxs 664 Good Unknown 0.1 MEIA 1.7 MEIA Recommend
34 Brazil Sucupira 2006 HIV patients xxs 44 Poor Unknown 27 ELISA n/c
35 Brazilc Tovo 2006 HIV patients xxs 343 Reasonable Unknown 4.6 IA 38.5 IA n/c
36 Brazilc Nunes 2007 Parakana indians xxs 258 Reasonable Unknown 3.9 EIA 20.0 EIA 53.5 EIA Concurrent
37 Brazil Zago 2007 HIV positive patients xxs 851 Reasonable Unknown 3.8 ELISA n/c
38 Brazilc Aquino 2008 Pop of Para xxs 11282 Good Unknown 3.6 EIA 37.7 MELISA Recommend
39 Brazilc Figueiredo 2008 Young women xxs 1029 Good 20-26 0.9 EIA 4.2 EIA n/c
40 Brazil Kupski 2008 Blood donors xxs 244 Reasonable Unknown 85.7 EIA n/c
41 Brazil Matos 2008 Long distance truck
drivers
xxs 641 Good Unknown 2.5 ELISA 18.3 ELISA Recommend
42 Brazil Miranda 2008 Young women xxs 1029 Reasonable-good 18-29 0.9 EIA 4.2 EIA Recommend
43 Brazil Motta-Castro 2008 Afro-Brazilian pop xxs 239 Good 2-87 8.4 ELISA n/c
44 Brazil Nascimento 2008 First-time blood donors xxs 3598 Good 18-62 0.33 ELISA 4.6 ELISA n/c
45 Brazil Tolentino 2008 Inﬂammatory bowel
disease patients
xxs 176 Reasonable 18-84 2.3 ELISA 17 ELISA Recommend
46 Brazil de Lima 2009 Pregnant women
(low-income)
xxs 202 Reasonable 12-41 1.0 MEIA n/c
46 Brazil de Lima 2009 Post-partum women
(low-income)
xxs 332 Reasonable 13-44 1.2 MEIA n/c
47 Brazil Ferreria 2009 Non-injecting drug
users
xxs 852 Poor-Reason 18+ 1.1 ELISA 22.2 ELISA 14 ELISA Recommend
48 Brazil Guimaraes 2009 Adults with mental
illness
xxs 2238 Good 18+ 1.6 ELISA 14.7 ELISA n/c
49 Brazil, Amazon Arboleda 1995 General pop xxs 798 Good 0-86 1.6 ELISA 21.4 ELISA n/c
50 Brazil, Amazon Santos 1995 Amerindian pop xxs 2222 Reasonable 1-80 3 EIA n/c
50 Brazil, Amazon Santos 1995 Urban pop xxs 2022 Reasonable 9-60 .9 EIA n/c
51 Brazil, Amazon Coimbra 1996 Amerindian pop xxs 449 Reasonable 0-50+ 2.0 NS 73.7 NS n/c
52 Brazil, Amazon Ferrari 1999 Amerindian pop xxs 119 Reasonable 1-76 3.4 RIA 35.3 RIA n/c
53 Brazil, Amazonc Brasil 2003 Household contacts
of HBV index cases
xxs 258 Reasonable 1-56 12.0 ELISA 51.6 ELISA n/c
54 Brazil, Amazonc Braga 2005 General pop xxs 605 Good Unknown 3.3 ELISA 49.9 ELISA n/c
55 Brazil, Amazon Viana 2005 General pop xxs 2656 Reasonable 0-92 3.3 ELISA 61.5 ELISA n/c
56 Brazil, Amazon Braga 2006 HIV/AIDS patients xxs 704 Good 0-50+ 6.4 ELISA 40.2 ELISA Recommend
57 Brazil, Amazon Lobato 2006 Children of HBsAg
positive women
xxs 48 Reasonable 0-16 10.4 ELISA 37.5 ELISA n/c
57 Brazil, Amazon Lobato 2006 Children of HBsAg
negative women
xxs 105 Reasonable 0-16+ 1.9 ELISA 6.8 ELISA n/c
1 Chile Silveira 1999 General pop xxs 496 Reas-Good 1-40 .6 ELISA Recommend
58 Colombiae Velandia 1997 Women xxs 246 Poor 15-50 4.1 ELISA 1.6 ELISA n/c
59 Dominican Republic Shichijo 1995 General pop (Group I) xxs 408 Poor-Reason 0-61+ 4.7 ELISA Prior
59 Dominican Republic Shichijo 1995 General pop (Group II) xxs 2000 Poor-Reason 20-70+ 3.2 RPHA Prior
1 Dominican Republic Silveira 1999 General pop xxs 473 Reasonable 1-40 1.9 RIA 21.4 RIA Recommend
60 Guadeloupe Viel 1995 Blood donors xxs 2339 Reas-Good 16-65 3.1 RIA 22.1 RIA n/c
61 Mexicoe Alvarez-
Munoz
1991 Relatives of HBsAg+
individuals
xxs 152 Poor Unknown 3.9 EIA Recommend
62 Mexicoe Oritz-Ibarra 1996 Pregnant women xxs 1500 Reasonable Unknown .26 ELISA 0 ELISA 1.86 ELISA n/c
63 Mexico Alverez-
Munoz
1997 Healthy pregnant
women
xxs 5130 Reasonable 12-49 .02 ELISA .87 ELISA n/c
63 Mexico Alverez-
Munoz
1997 Pregnant women
w/complications
xxs 1123 Reasonable 12-49 .09 ELISA .36 ELISA n/c
64 Mexicoe Ayala-Gaytan 1997 Blood donors xxs 78566 Good 18-85 .16 IA 2 IA n/c
65 Mexicoe Pita-Ramirez 1997 Blood donors xxs 10077 Good 18-60 .33 EIA n/c
66 Mexicoe Mendez-San-
chez
1999 Blood donors xxs 9099 Reas-Good Unknown .11 ELISA n/c
1 Mexico Silveira 1999 General pop xxs 5212 Good 1-40 .1 EIA 1.4 ELISA Recommend
67 Mexicoc Alvarado-
Esquivel
2006 Acute and chronic
liver disease patients
xxs 65 Poor Unknown 3.1 IA n/c
68 Mexico Mendez-San-
chez
2006 Nurses xxs 379 Poor Unknown 1.6 IA Recommend
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Appendix B (Continued )
Country Source Source
Year
Population studied Study
designa
Sample
size
Study quality Age range HBsAg
preva-
lence (%)
Testing
Method
Used
HBeAg
preva-
lenceb (%)
Testing
Method
Used
Anti-HBc
preva-
lencec (%)
Testing
Method
Used
Vaccination
Interventiond
69 Mexico Calderon 2009 Transfusion patients xxs 300 Good 5-75 7 EIA n/c
70 Puerto Rico Deseda 1995 Pregnant women xxs 992 Reasonable 15-30+ .4 RIA 9.2 RIA n/c
71 Venezuelae Ponce 1994 Adults xxs 146 Poor-Reason 20-90 2.1 EIA 28 EIA n/c
72 Venezuela Blitz-Dort-
man
1996 General Amerindian
pop
xxs 293 Reasonable Unknown 7.4 EIA 66.8 EIA n/c
73 Venezuelae Leon 1998 Blood donors xxs 53338 Good Unknown .076 ELISA 5.28 NS n/c
1 Venezuela Silveira 1999 General pop xxs 469 Reasonable 1-40 3.2 ELISA Recommend
74 Venezuelac Monsalve-
Castillo
2008 Amerindian pop xxs 149 Poor 5-65+ 29.5 EIA 6.8 EIA 77.9 EIA n/c
WHO AMR-D Region
1 Bolivia Konomi 1999 Blood donors xxs 574 Reasonable 17-56 .3 PA n/c
2 Boliviae Leon 1999 Amerindian pop xxs 366 Reasonable Unknown 74 EIA Recommend
2 Boliviae Leon 1999 Rural pop xxs 187 Reasonable Unknown 11.2 EIA Recommend
2 Boliviae Leon 1999 Urban pop xxs 198 Reasonable Unknown 11.6 EIA Recommend
3 Nicaragua Perez 1996 General pop xxs 447 Reas-Good 2+ .9 EIA n/c
4 Perue Vildosola 1990 General pop xxs 680 Reasonable Unknown 3.8 ELISA Recommend
5 Peruc Vildozola 2006 Pregnant adolescents xxs 1048 Poor-Reason 14-19 0.67 ELISA 3.53 ELISA n/c
WHO EMR-B Region
1 Iran Amini 1993 General pop xxs 4930 Good 0-69+ 2.5 ELISA 13.8 ELISA 5.1 ELISA n/c
2 Iran Jahani 2003 Large vehicle drivers xxs 1113 Good 18-70 5.9 ELISA Recommend
3 Iran Alizadeh 2005 General pop xxs 1824 Good >5 2.3 ELISA 7.8 ELISA Recommend
4 Iran Alizadeh 2006 General pop xxs 1824 Reasonable 6-93 2.3 ELISA 7.8 ELISA Recommend
5 Iran Vahdani 2006 Street children xxs 102 Poor <15 3.0 ELISA n/c
6 Iran Talaie 2007 Non-IV drug
opioid poisoned patients
xxs 214 Good 16-87 1.86 EIA n/c
7 Iran Pourkarim 2008 Afghan refugees xxs 74 Poor 28-60 60.8 NS 14.7 NS 85.1 NS n/c
8 Iran Amini Kaﬁ-
Abad
2009 Blood donors xxs 6499851 Good <29-50+ 0.56 IA Recommend
9 Iran Merat 2009 General pop xxs 6583 Good 18-65 2.6 ELISA 16.4 ELISA Recommend
10 Iran Ramezani 2009 HIV patients xxs 29 Reasonable Unknown 0 ELISA 17.2 ELISA n/c
10 Iran Ramezani 2009 HIV-HCV
coinfected patients
xxs 63 Reasonable Unknown 6.6 ELISA 28.6 ELISA n/c
11 Jordan Toukan 1990 General pop xxs 1115 Good 0-60+ 9.9 RIA 31.8 RIA Prior
12 Jordan Batayneh 2002 Pregnant women xxs 1000 Reas-Good 15-44 4.3 ELISA 2.3 ELISA 11.1 ELISA Recommend
13 Lebanon Nabulsi 1997 Pregnant women xxs 558 Reas-Good 16-44 2.9 ELISA 6.3 ELISA Recommend
14 Lebanon Nabulsi 2001 Children xxs 841 Good 0-6 .12 ELISA Recommend
15 Lebanon Irani-Hakime 2006 Blood donors xxs 16084 Good Unknown 0.9 ELISA n/c
16 Lebanon Saab 2007 General pop xxs 2634 Good 14-71 1.6 ELISA Prior
17 Lebanon Ramia 2008 HIV patients xxs 101 Poor 25-60 6.9 IA 23.8 ELISA n/c
18 Oman Kaminski 2006 Blood donors xxs 200 Poor-Reason Unknown 20.5 EIA n/c
19 Saudi Arabia Bahakim 1991 Adults males xxs 500 Good 18-55 28 EIA n/c
19 Saudi Arabia Bahakim 1991 Pregnant women xxs 260 Good 16-40 28.5 EIA n/c
20 Saudi Arabia Al-Faleh 1992 Children xxs 4575 Poor 1-10 6.7 ELISA 4.2 ELISA Prior
21 Saudi Arabia Abdelaal 1994 Male blood donors xxs 744 Good Unknown 6.2 EIA 28.7 EIA n/c
22 Saudi Arabia Fathalla 1998 Pregnant women xxs 74405 Good 18-40 6.1 ELISA Prior
22 Saudi Arabia Fathalla 1998 Children xxs 12360 Good 0-15 4.8 ELISA Prior
22 Saudi Arabia Fathalla 1998 Male blood donors xxs 126863 Good 18-49 6.8 ELISA Prior
23 Saudi Arabia Mehdi 2000 Male blood donors xxs 11007 Good 18-60 3.4 ELISA n/c
24 Saudi Arabia Al-Sebayel 2002 Liver donors xxs 145 Reasonable Unknown 35.2 NS n/c
25 Saudi Arabia Ayoola 2003 Blood donors xxs 14883 Good Unknown 5.4 EIA Post
25 Saudi Arabia Ayoola 2003 General pop xxs 1172 Good Unknown 5.1 EIA Post
25 Saudi Arabia Ayoola 2003 Hospital patients xxs 4692 Good Unknown 9.7 EIA Post
26 Saudi Arabia Al-Mazrou 2004 Pregnant women xxs 2664 Good Unknown 2.46 ELISA Concurrent
27 Saudi Arabia Jaber 2006 School children xxs 527 Reasonable-Good 4-14 75.0 ELISA Recommend
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28 Saudi Arabia Alrowaily 2008 Pregnant women xxs 755 Good Unknown 1.6 ELISA Recommend
29 Saudi Arabia El Beltagy 2008 Blood donors xxs 3192 Reas-Good 18-52 3.0 EIA 18.7 EIA Recommend
30 Saudi Arabia Al-Wayli 2009 Hospital patients xxs 79858 Reasonable Unknown 3.1 NS Concurrent
31 Tunisia Triki 1997 Male military recruits xxs 31624 Good 20-25 6.3 ELISA Recommend
31 Tunisia Triki 1997 General pop xxs 785 Good 0-60 6.5 ELISA Recommend
31 Tunisia Triki 1997 Infants xxs 477 Good 3 months .4 ELISA Recommend
31 Tunisia Triki 1997 Mothers xxs 477 Good Unknown 3.8 ELISA Recommend
32 United Arab Emi-
rates
Al-Owais 2000 General pop xxs 8713 Reasonable 5-80 2.8 MEIA Prior
33 West Bank/Gaza
Strip
Nashef 1992 General pop xxs 778 Good 0-50 1.8 ELISA Prior
WHO EMR-D Region
1 Djiboutic Dray 2005 Blood donors xxs 9006 Good Unknown 10.4 ELISA n/c
2 Egypt Kamel 1994 General pop xxs 1259 Good 0-69 2.1 EIA n/c
3 Egypt Darwish 1996 General pop xxs 153 Poor-Reason 1-67+ 1.3 EIA n/c
4 Egypt El-Nawawy 1996 Pregnant women xxs 150 Reas-Good Unknown 8 EIA 0 EIA Recommend
4 Egypt El-Nawawy 1996 Newborns xxs 12 Reas-Good Unknown 17 EIA 0 EIA Recommend
5 Moroccoc Boulaajaj 2005 Haemodialysis patients xxs 186 Reasonable Unknown 2.2 ELISA Recommend
6 Pakistan Kakepoto 1996 Blood donors xxs 51257 Good 16-68 2.3 MEIA Concurrent
7 Pakistan Abbas 1997 Children xxs 664 Reas-Good 0-12 3.6 ELISA n/c
8 Pakistan Luby 1997 General pop xxs 291 Good 0-60+ 4.3 EIA 31 EIA n/c
9 Pakistan Akhtar 2005 Blood donors xxs 351309 Good Unknown 2.0 ELISA n/c
10 Pakistan Abbas 2006 General pop xxs 11372 Good 11-66 4.3 IC 20 IC Recommend
11 Pakistan Jafri 2006 Children xxs 3533 Good 1-15 1.8 ELISA Recommend
12 Pakistan Quddus 2006 Afghan refugees xxs 903 Good 0-50+ 8.3 IA Recommend
13 Pakistan Mahboob 2007 General pop xxs 200 Poor-Reason Unknown 3.5 ELISA n/c
13 Pakistan Mahboob 2007 Lichen planus patients xxs 200 Poor-Reason Unknown 1.5 ELISA n/c
14 Pakistan Sami 2009 Pregnant women xxs 5902 Reasonable Unknown 4.6 EIA Recommend
14 Pakistan Sami 2009 Gynecological
surgery patients
xxs 548 Reasonable Unknown 12 EIA Recommend
15 Somalia Bile 1992 Children xxs 672 Good 1-15 15 NS n/c
16 Somaliae Mohamud 1992 General pop xxs 1272 Reasonable 0-83 19.2 EIA n/c
17 Somalia Nur 2000 Blood donors xxs 115 Reas-Good 18-40 19 NS Recommend
17 Somalia Nur 2000 Hospitalized adults xxs 47 Reas-Good 17-66 21 NS Recommend
17 Somalia Nur 2000 Hospitalized children xxs 36 Reas-Good 0-9 5.6 NS Recommend
18 Sudan Elshaﬁe 1992 Male blood donors xxs 110 Reasonable Unknown 17 RPHA n/c
19 Sudan Fahal 1995 General pop xxs 150 Poor 8-80 12 ELISA 13 ELISA n/c
20 Sudan Khalil 1996 Blood donors xxs 1217 Reasonable 18-55 4 CIEP n/c
WHO EUR-A Region
1 Belgium Beutels 1997 General pop xxs 3866 Poor 0-65 .7 RIA .6 RIA Recommend
2 Belgium Quoilin 2007 General pop xxs 1834 Reasonable 0-65+ 0.66 ELISA Recommend
3 Croatia Jelic 1994 General pop xxs 2142 Poor-Reason 0-51 1.8 ELISA Recommend
4 Croatia Ivic 1999 Pregnant women xxs 400 Good 17-43 .75 ELISA 7.5 MEIA n/c
5 Cyprus Kurugl 2009 General Turkish pop xxs 585 Good 1-30 0.85 ELISA 13.2 ELISA Post
5 Cyprus Kurugl 2009 General Turkish pop
under 8 yr/old
xxs 142 Good 1-7 0 ELISA 7.0 ELISA Post
6 Denmark Nelsing 1995 Adult patients xxs 466 Good 18-96 .85 ELISA 11.8 ELISA Recommend
7 Denmarke Dickmeiss 2001 Blood donors xxs 100 Poor-Reason 18-60 0 ELISA n/c
8 Francee Ranger 1990 Pregnant women xxs 9570 Good 13-47 .54 ELISA 27 ELISA n/c
8 Francee Ranger 1990 Male blood donors xxs 72769 Good Unknown .05 ELISA n/c
8 Francee Ranger 1990 Female blood donors xxs 60049 Good Unknown .03 ELISA n/c
9 Francee Soulie 1991 Pregnant women xxs 6605 Good Unknown 2.3 IA 14.0 EIA Recommend
10 France Goudeau 1995 General pop xxs 5641 Reas-Good 6-60 .2 NS .5 NS Concurrent
11 Francee Pillonel 1998 First time blood donors xxs 416000 Good 18-65 .17 NS n/c
11 Francee Pillonel 1998 Repeat blood donors xxs 1347000 Good 18-65 .002 NS n/c
12 Francee Monchar-
mont
2000 Blood donors xxs 12456 Good 18-65 1.3 RIA n/c
13 France Denis 2004 Pregnant women xxs 22859 Good 14-40+ 0.65 IA Recommend
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14 France Zarski 2006 Chronic Hepatitis B
patients
xxs 865 Good Unknown 72.0 ELISA n/c
15 France Larsen 2008 HIV patients xxs 1849 Reasonable Unknown 7.0 NS 23.7 NS Recommend
16 Germany Peterson 1992 Blood donors xxs 381 Good Unknown 0 NS 3.8 NS Recommend
17 Germany Bolke 1995 Young adults xxs 1600 Reas-Good 19-27 .4 RIA 7.1 RIA n/c
17 Germany Bolke 1995 Adults xxs 400 Reas-Good >50 1.5 RIA 32.5 RIA n/c
18 Germanye Niesert 1996 Pregnant women xxs 912 Reasonable Unknown 1.4 EIA 6.4 EIA n/c
19 Germany Jilg 2001 General adult pop xxs 5305 Reas-Good 18-70 .6 MEIA 8.7 MEIA Concurrent
20 Germany Knorr 2008 Women of reproductive
age
xxs 5518 Poor-Reas 16-45 1.6 IA 8.0 IA Recommend
21 Greece Dalekos 1996 General pop ccs 1342 Poor Unknown 2.1 EIA 19.5 EIA n/c
22 Greece Lionis 1997 Children xxs 304 Good 5-16 .3 MEIA 2.3 MEIA Recommend
23 Greece (Crete) Lionis 1997 General adult pop xxs 257 Poor 15+ 1.2 MEIA 24.5 MEIA Prior
23 Greece (Crete) Lionis 1997 General pop xxs 164 Poor 1-65+ 0 MEIA 9.8 MEIA Prior
24 Greecee Doutsos 1998 Medical students xxs 494 Reasonable Unknown 1.2 MEIA Prior
25 Greecee Gioka 1998 Adults xxs 261 Reasonable Unknown 0 MEIA 8.4 MEIA Prior
26 Greecee Zervou 1998 Blood donors xxs 6696 Good 18-60 .85 MEIA Concurrent
27 Greece (Crete) Koulentaki 1999 Adult blood donors xxs 65219 Reas-Good <20-60 .4 MEIA n/c
28 Greece Stamouli 1999 Young male pop xxs 1050 Reasonable 18-25 .95 MEIA 20 MEIA 1.0 MEIA Concurrent
29 Greece Kyriakis 2000 General pop xxs 288129 Reas-Good 18-61 .8 EIA Concurrent
30 Greece Dounias 2005 Municipal
solid waste workers
xxs 166 Poor-Reas Unknown 7.2 ELISA Recommend
31 Greece Papaevange-
lou
2008 Children xxs 1286 Poor-Reas 0-14 0.6 ELISA 5.6 ELISA Post
32 Iceland Briem 1990 Outpatients xxs 455 Poor-Reason Unknown .14 ELISA 5.4 ELISA Recommend
33 Israel Bar-Shany 1991 Male blood donors xxs 39011 Reas-Good 18-65 1.1 ELISA Recommend
33 Israel Bar-Shany 1991 Female blood donors xxs 10196 Reas-Good 18-65 .44 ELISA Recommend
34 Israel Bogomolski 1991 Pregnant women xxs 11123 Reas-Good Unknown .9 RIA & EIA 1.6 RIA & EIA Prior
35 Israel Isacsohn 1994 Pregnant women xxs 6572 Good Unknown .6 EIA Recommend
36 Israel Glikberg 1997 Migrant pop xxs 102 Poor 17-84 15.7 EIA n/c
37 Italy Stroffolini 1990 Adolescents xxs 1357 Good 14-19 1.1 NS n/c
38 Italy Chiaramonte 1991 Children xxs 1635 Good 6-15 .1 ELISA .1 ELISA Concurrent
39 Italy Stroffolini 1991 Children xxs 7405 Good 3-19 .6 ELISA Prior
40 Italy D’Amelio 1992 Male military recruits xxs 4993 Reasonable 18-26 1.6 NS 5.8 NS Recommend
41 Italy Puro 1992 Pregnant women xxs 1142 Poor-Reason 14-47 1.6 ELISA 14.4 ELISA Recommend
42 Italy Adamo 1998 Pregnant women xxs 1887 Good Unknown 2.5 NS Post
43 Italy Baldo 2000 Pregnant women xxs 2059 Good 16-50 1.0 EIA n/c
44 Italy Bruno 2007 Medical students xxs 2137 Poor-Reason Unknown 1.0 EIA n/c
45 Italy Manzini 2007 Blood donors xxs 6313 Good 18-69 4.85 MEIA Recommend
46 Italy Majori 2008 Sub-Saharan
immigrants
xxs 182 Poor 0-60 9.3 EIA 58.3 EIA Recommend
47 Italy Raimondo 2008 Individuals w/o
hepatic disease
xxs 98 Poor Unknown 16.3 EIA n/c
48 Italy Trevisan 2008 Medical school students xxs 2361 Poor-Reason Unknown 1.0 EIA Recommend
49 Italy Camoni 2009 Drug users xxs 1330 Good Unknown 24.6 EIA 46.2 EIA Recommend
50 Italy Scognamiglio 2009 General adult pop xxs 577 Reasonable 23-26 3.3 EIA Recommend
51 Italy Stratta 2009 Renal transplant
candidates
xxs 300 Poor-Reason 20-75 71.0 NS n/c
52 Netherlands Grosheide 1995 Pregnant women xxs 99706 Good Unknown .7 RIA & ELISA 16.7 RIA & ELISA n/c
53 Portugale Santos 2000 Adults xxs 657 Reas-Good 20-65 .91 ELISA 1.82 ELISA Recommend
54 Republic of Ireland O’Connell 2000 General pop xxs 1714 Good 0-65+ 0 IA .29 IA n/c
55 Spain del Olmo 1990 Prison staff xxs 154 Reasonable 18-60 1.3 EIA Recommend
56 Spaine Delgado-San-
chez
1990 Pregnant women xxs 454 Reas-Good Unknown 3.1 NS Recommend
57 Spaine Munoz Calvo 1990 Healthy children xxs 375 Reas-Good 6-14 1.3 ELISA 4.0 ELISA Prior
58 Spain Dal-Re 1991 General pop xxs 497 Poor 0-75 .8 ELISA 1.4 ELISA Concurrent
59 Spain Salleras 1992 Children xxs 1017 Good 6-14 .5 NS Prior
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59 Spain Salleras 1992 General adult pop xxs 661 Good 15-65+ 1.7 NS Prior
60 Spaine Virto Ruiz 1993 Cigane pop xxs 245 Reasonable 0-75 27 ELISA Recommend
60 Spaine Virto Ruiz 1993 Gypsy pop xxs 127 Reasonable 0-78 0 ELISA Recommend
60 Spaine Virto Ruiz 1993 General pop xxs 103 Reasonable 3-82 .9 ELISA Recommend
61 Spaine Panizo-Del-
gado
1994 Pregnant women xxs 2499 Reasonable 14-45 .7 EIA 16.6 EIA 7.5 EIA Prior
62 Spaine Suarez 1994 Blood donors xxs 42789 Good 18-65 .16 ELISA Recommend
63 Spaine Cortes 1995 Adolescents xxs 262 Reasonable 12-15 .38 ELISA 16.7 MEIA 1.1 ELISA Recommend
64 Spaine Bayas 1996 Health science
students
xxs 1734 Reasonable Unknown 2.5 ELISA Recommend
65 Spain Garcia-Ful-
gueiras
1996 General adult pop xxs 2203 Reasonable 18-65 .9 ELISA 10.2 ELISA n/c
66 Spaine Suarez 1996 Young adults xxs 433 Reasonable 6-25 .46 ELISA 1.8 ELISA Recommend
67 Spaine Suarez 1997 Adults xxs 331 Reas-Good 26-65 1.2 ELISA 11.8 ELISA Recommend
68 Spain Gil 1998 Urban adolescents xxs 642 Reasonable 14-17 3.7 ELISA Recommend
68 Spain Gil 1998 Rural adolescents xxs 547 Reasonable 14-17 2.2 ELISA Recommend
69 Spain Santana
Rodriguez
1998 Non-injection drug
users
xxs 263 Poor-Reason 15-58 2.7 ELISA 20.7 ELISA n/c
70 Spain Dominguez 2000 General pop xxs 2142 Good 5-64+ 1.2 ELISA 9.1 ELISA Concurrent
71 Spainc Sola 2002 General pop xxs 2194 Reas-Good 25-74 1.7 n/c
72 Spain Enriquez 2007 Glomerular disease
patiants
xxs 89 Poor Unknown 0.0 EIA 9.0 EIA n/c
72 Spain Enriquez 2007 Blood donors xxs 59546 Poor Unknown 0.28 EIA n/c
73 Spain Salleras 2007 General pop xxs 2620 Good 5-65+ 0.7 ELISA 8.7 ELISA Post
74 Spain Solves 2008 Blood donors xxs 6855 Good Unknown 0.68 IA 11.4 EIA n/c
75 Spainc Valerio 2008 Recent immigrants xxs 791 Poor-Reas Unknown 5.9 EIA 33 EIA n/c
76 Spain Vallejo 2008 Non-injecting heroin
users
xxs 276 Poor-Reason < 30 17.2 EIA Recommend
76 Spain Vallejo 2008 Injecting heroin users xxs 460 Poor-Reason < 30 22.5 EIA Recommend
77 Spain Loras 2009 Chrohn’s disease patients xxs 1128 Good Unknown 0.6 ELISA 7.1 ELISA Recommend
77 Spain Loras 2009 Ulcerative colitis patients xxs 928 Good Unknown 0.8 ELISA 8.0 ELISA Recommend
78 Spain Marcos 2009 Sjogren’s
syndrome patients
xxs 603 Good 31-89 0.83 ELISA n/c
79 Sweden Struve 1992 General adult pop xxs 4000 Good 12-54 .25 RIA 1.8 RIA Recommend
80 Sweden Christenson 1997 Adults xxs 3382 Good 18-90 .06 EIA 2.6 EIA n/c
81 Sweden Hoffman 2000 Adults xxs 5533 Good Unknown .2 ELISA 4.2 ELISA n/c
82 Switzerland Bart 1996 Pregnant women xxs 9006 Good 15-51 .8 EIA 7.1 EIA Recommend
83 United Kingdom Boxall 1994 Pregnant women xxs 3522 Good Unknown .6 RIA Recommend
84 United Kingdom Hesketh 1997 Children xxs 2025 Good 13-14 .15 ELISA Recommend
85 United Kingdom Gay 1999 Adults xxs 3781 Good 15-44 3.9 EIA Prior
86 United Kingdom Aweis 2001 Somali pop in Liverpool xxs 439 Poor-Reason 0-80 5.7 ELISA 27.5 ELISA Recommend
87 United Kingdom Kawsar 2002 Chinese pop xxs 117 Poor 17-69 12.8 NS 58.8 NS Recommend
88 United Kingdom
(Scotland)
McMillan 2006 MSM who attended
an STI clinic
xxs 3334 Reasonable Unknown 1 IA 12 IA Recommend
WHO EUR-B Region
1 Albania Da Villa 1995 General pop xxs 1348 Poor Unknown 11.7 IA 15.8 IA 57.9 IA Recommend
1 Albania Da Villa 1995 Children xxs 46 Poor 0-5 15.2 IA 56.5 IA Recommend
1 Albania Da Villa 1995 Pregnant women xxs 196 Poor Unknown 11.7 IA 17.4 IA 71.4 IA Recommend
2 Albania Resuli 2009 Schoolchildren xxs 410 Good Unknown 11.8 ELISA Recommend
2 Albania Resuli 2009 Students xxs 666 Good Unknown 8.7 ELISA Recommend
2 Albania Resuli 2009 Military personnel xxs 500 Good Unknown 10.6 ELISA Recommend
2 Albania Resuli 2009 Casual blood donors xxs 1286 Good Unknown 8.9 ELISA Recommend
2 Albania Resuli 2009 Voluntary blood donors xxs 378 Good Unknown 9.6 ELISA Recommend
2 Albania Resuli 2009 Pregnant women xxs 640 Good Unknown 7.3 ELISA Recommend
3 Bosnia & Herzego-
vina
Puvacic 1991 Pregnant women xxs 63 Poor 17-39 4.8 NS Recommend
4 Bulgaria Vassilev 2006 Intravenous drug users xxs 773 Poor-Reason Unknown 6 ELISA n/c
5 Georgia Badridze 2008 HIV positive patients xxs 175 Reasonable 20-77 6.9 ELISA 43.4 ELISA Recommend
6 Greenland Langer 1997 General pop xxs 503 Good 7-79 7 IA 42 IA n/c
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7 Poland Chlabicz 2006 Social assistance
home patients
xxs 1163 Poor-Reason Unknown 2.8 ELISA Recommend
8 Polandc Grzegor-
zewska
2008 Hemodialysis patients xxs 1140 Reasonable Unknown 3.4 NS 32.7 NS n/c
9 Romaniae Iacob 1993 Blood donors xxs 2049 Reasonable Unknown 3.8 ELISA Concurrent
10 Romania Paquet 1993 Children xxs 201 Reasonable 0-16 19.9 ELISA Recommend
10 Romania Paquet 1993 Pregnant women xxs 204 Reasonable 14-42 7.8 ELISA Recommend
10 Romania Paquet 1993 Adults xxs 200 Reasonable 16-82 11 ELISA Recommend
11 Romania Woodruff 1993 Pregnant women xxs 573 Good 15-45 8.4 RIA 2.0 RIA 28 RIA Prior
12 Romaniae Bocsan 1994 Orphanage children cos 173 Poor-Reason Unknown 24.8 ELISA Post
13 Romaniae Beldescu 1995 General pop xxs 869 Reasonable 1-60+ 20.7 ELISA n/c
14 Romaniae Debeleac 1995 Patients xxs 7589 Good Unknown 13.7 ELISA n/c
15 Romania Molnar 1995 Pregnant women xxs 2354 Good Unknown 3.8 ELISA 8.9 ELISA Recommend
16 Romaniae Iancu 1997 Children xxs 517 Reasonable 0-14+ 24.28 ELISA Recommend
17 Romaniae Balan 1998 Pregnant women xxs 1298 Reasonable <20-40+ 12.2 ELISA 25.3 ELISA Recommend
18 Romania Brehar-Cio-
ﬂec
1998 General pop xxs 226 Poor Unknown 19.9 EIA 55.3 EIA n/c
19 Romania Ruta 2005 HIV positive adolescents xxs 161 Reasonable 13-18 43.4 EIA 25.7 EIA 78.3 EIA Post
19 Romania Ruta 2005 Adolescent pop xxs 356 Reasonable 13-18 7.9 EIA 28.6 EIA 31.7 EIA Post
20 Romaniac Duca 2007 General pop xxs 220 Poor-Reason 20+ 33.2 NS 25.4 NS n/c
21 Turkeye Mistik 1993 Pregnant women xxs 602 Poor Unknown 3.1 ELISA 21 ELISA n/c
21 Turkeye Mistik 1993 Infants of HBsAg +
mothers
xxs 19 Poor 0-1 31 ELISA 33.3 ELISA n/c
22 Turkey Cetinkaya 1995 Children xxs 1316 Poor-Reason 0-10+ 3.2 ELISA Recommend
23 Turkeye Poyraz 1995 General pop xxs 400 Poor Unknown 7.5 ELISA 4.2 ELISA n/c
24 Turkeye Kilic 1996 Adults xxs 532 Reasonable 19-68 7.5 ELISA Recommend
25 Turkey Kuru 1995 General pop xxs 801 Good 0-60 12 ELISA 37.8 ELISA Prior
26 Turkey Kuru 1996 Pregnant women xxs 5366 Reasonable Unknown 4.2 EIA 6.2 EIA n/c
27 Turkey Nas 1999 Pregnant women xxs 3050 Poor-Reason 17-39 1.3 NS n/c
28 Turkeye Sayiner 1999 General pop xxs 1920 Reasonable Unknown 3.1 RPHA n/c
29 Turkey Okan 2002 Type 2 diabetic patients xxs 692 Good Unknown 5.3 ELISA Recommend
29 Turkey Okan 2002 Blood donors xxs 1014 Good Unknown 5.1 NS Recommend
30 Turkey Erden 2003 Hospital patients xxs 1157 Good 15-85 6.6 ELISA Recommend
31 Turkey Erol 2003 Family members of
HbsAg positive
individuals
xxs 244 Poor-Reason Unknown 29.6 ELISA 43.8 ELISA n/c
31 Turkey Erol 2003 Blood donors xxs 384 Poor-Reason Unknown 9.6 ELISA 29.7 ELISA n/c
32 Turkey Mehmet 2005 General pop xxs 3000 Good 15-64+ 7.0 MEIA 47.4 MEIA n/c
33 Turkey Gurol 2006 Blood donors xxs 6240130 Good Unknown 4.19 ELISA Recommend
34 Turkey Guven 2006 Workers with no
known occupational expo-
sure
xxs 571 Reasonable 21-51 6.6 ELISA 50.6 ELISA n/c
35 Turkey Ucmak 2007 Family members of
HbsAg positive patients
xxs 2113 Reasonable Unknown 30.5 EIA n/c
36 Turkey Demir 2008 Type 2 diabetes patients xxs 576 Good Unknown 3.9 MEIA n/c
37 Turkey Okan 2008 Lymphoproliferative
disorder patients
xxs 334 Poor Unknown 6.2 ELISA n/c
37 Turkey Okan 2008 Blood donors xxs 1014 Poor Unknown 4.9 ELISA n/c
38 Turkey Yildirim 2009 General pop xxs 1095 Reas-Good 18-95 5.5 EIA 12.1 EIA n/c
WHO EUR-C Region
1 Belaruse Kalinin 1998 Patients xxs 26740 Reasonable 0-50 5.1 NS n/c
2 Hungary Ordog 2003 Family members
of pregnant women
HBV carriers
xxs 391 Poor Unknown 27.1 ELISA 50.4 ELISA n/c
3 Lithuaniae Caplinskas 2000 Adolescents xxs 632 Poor 14-19 1.42 NS n/c
4 Lithuania Kupcinskas 2007 Soldiers xxs 1830 Poor-Reason Unknown 2.0 NS Recommend
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5 Moldova Drobeniuc 1999 Children xxs 439 Good 0-6 6.8 RIA 17.1 RIA Prior
5 Moldova Drobeniuc 1999 Pregnant women xxs 1098 Good Unknown 9.7 RIA 35.6 EIA 52.4 RIA Prior
6 Russian Federatione Aryamkina 1990 Blood donors xxs 3358 Good 23-44 1.3 NS n/c
7 Russian Federatione Kuzin 1990 Pregnant women
(Moscow)
xxs 18652 Reasonable Unknown 1.1 NS 5.2 NS Recommend
7 Russian Federatione Kuzin 1990 Pregnant women
(Uzbekistan)
xxs 6142 Reasonable Unknown 6.9 NS 13.9 NS Recommend
8 Russian Federatione Frolov 1991 General pop xxs 3258 Poor-Reason Unknown 3.8 RIA 31.4 RIA n/c
9 Russian Federatione Yashina 1992 Blood donors (Moscow) xxs 1040 Reasonable 0-70 2.0 NS 4.5 NS n/c
9 Russian Federatione Yashina 1992 Blood donors
(Osh District)
xxs 979 Reasonable 0-70 10.3 NS 14.0 NS n/c
10 Russian Federatione Dvornikov 1995 General pop xxs 1287 Poor 0-88 8.3 EIA n/c
11 Russian Federatione Sailov 1995 Hospital patients xxs 20535 Reasonable Unknown 4.2 NS 6.2 NS n/c
12 Russian Federation Ohba 1999 Adults xxs 348 Reas-Good 16-82 11.8 PA Recommend
13 Russian Federationc Fedorchenko 2008 Blood donors xxs 14366 Good Unknown 6.8 NS n/c
14 Ukrainee Schastnyi 1996 Students xxs 1508 Reasonable 0-15 1.6 NS n/c
WHO SEAR-B Region
1 Indonesia Amirudin 1991 Adults xxs 196 Reasonable 0-59 7.1 RPHA & EIA 76 HI n/c
2 Indonesia Budihusodo 1991 Blood donors xxs 243 Reasonable Unknown 5.8 RPHA 59.3 HI n/c
3 Indonesia Sulaiman 1995 Adults xxs 3839 Reas-Good 11-76 8.8 ELISA n/c
4 Indonesia Surya 2005 Pregnant
women
xxs 2450 Poor-Reason 16-45 1.9 RPHA 28.3 ELISA n/c
5 Sri Lanka Padmasiri 1995 General pop xxs 1913 Good < 6 mo 2.5 ELISA Recommend
6 Thailand Tanprasert 1993 Blood donors xxs 74,530 Reasonable Unknown 6.45 RPHA Recommend
7 Thailande Vithayasai 1993 College students xxs 1010 Reasonable Unknown 9.61 RPHA n/c
8 Thailand Nelson 1994 General pop xxs 961 Good 0-60+ 24.8 ELISA n/c
9 Thailand Luksamijar-
ulkul
1995 Children xxs 165 Reasonable 6-14 3.6 EIA 6.1 EIA Recommend
10 Thailand Songsivilai 1997 Blood donors xxs 3255 Good 17-68 4.9 EIA n/c
11 Thailande Bejrachandra 1998 Blood donors xxs 274288 Good Unknown 1.13 ELISA n/c
12 Thailand Chub-uppa-
karn
1998 Children xxs 180 Good 0-15 .55 ELISA 3.3 ELISA Post
13 Thailand Ikeda 1998 Females xxs 52 Reasonable 19-57 0 RIA 25 RIA n/c
14 Thailand Kozik 2000 Children xxs 1,903 Good 4-15 16 NS 27 NS Recommend
15 Thailand Chongsrisa-
wat
2006 General pop xxs 6213 Reas-Good 0-60 4 ELISA 26.5 ELISA Post
15 Thailand Chongsrisa-
wat
2006 Children born
after
immunization
intervention
xxs 2303 Reas-Good 0-18 0.7 ELISA 2.9 ELISA Post
15 Thailand Chongsrisa-
wat
2006 Children born
before
immunization
intervention
xxs 584 Reas-Good 18 4.3 ELISA 15.8 ELISA Post
WHO SEAR-D Region
1 Bangladesh Akhter 1992 Pregnant
women
xxs 500 Reas-Good Unknown 3.6 RPHA n/c
2 Bangladesh Laskar 1997 School girls xxs 836 Reasonable 6-15 2.3 LATEX n/c
2 Bangladesh Laskar 1997 School girls xxs 836 Reasonable 6-15 .8 ELISA n/c
3 Bangladesh Rahman 1997 General pop xxs 1000 Good Unknown 6.4 LATEX n/c
4 Bangladesh de Francisco 1999 Infants xxs 334 Good <1 .3 ELISA 0 ELISA 10.5 ELISA n/c
4 Bangladesh de Francisco 1999 Pregnant women xxs 330 Good 15-35+ 5.4 ELISA 22 ELISA 32.4 ELISA n/c
5 Bhutan Da Villa 1997 General pop xxs 1,666 Good 0-24+ 5.9 RIA 63.1 RIA Recommend
5 Bhutan Da Villa 1997 Pregnant women xxs 440 Good Unknown 5.4 RIA 29 ELISA Recommend
6 India Joshi 1990 School children xxs 1314 Reasonable 6-18 15.7 RPHA n/c
7 India Sarkar 1990 Newborns xxs 150 Poor-Reason <1 5.3 ELISA n/c
8 India Singhvi 1990 Blood donors xxs 2702 Reasonable Unknown 1.4 RPHA & ELISA n/c
8 India Singhvi 1990 Replacement
donors
xxs 32693 Reasonable Unknown 2.96 RPHA & ELISA n/c
9 India Thakur 1990 General pop xxs 2405 Reasonable Unknown 6.8 RPHA n/c
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Appendix B (Continued )
Country Source Source
Year
Population studied Study
designa
Sample
size
Study quality Age range HBsAg
preva-
lence (%)
Testing
Method
Used
HBeAg
preva-
lenceb (%)
Testing
Method
Used
Anti-HBc
preva-
lencec (%)
Testing
Method
Used
Vaccination
Interventiond
10 India Elavia 1991 Blood donors xxs 10433 Reas-Good Unknown 2.0 RPHA n/c
10 India Elavia 1991 Medical
personnel
xxs 606 Reas-Good Unknown 6.6 RPHA n/c
11 India Tandon 1991 Children xxs 982 Good 0-5 2.1 ELISA Prior
12 India Thakur 1991 Blood donors xxs 1274 Reasonable Unknown 2.6 ELISA n/c
13 India Irshad 1992 Blood donors xxs 1117 Reas-Good Unknown 5.7 RPHA & LATEX n/c
14 India Jain 1992 Patients xxs 202 Poor Unknown 11.3 RPHA n/c
15 India Satoskar 1992 Blood donors xxs 3014 Reasonable 18-65 4.7 ELISA n/c
16 India Dutta 1994 Hospital
patients
xxs 184 Poor 1-60+ 28.3 ELISA Recommend
17 India Irshad 1994 Adult blood
donors
xxs 20435 Reasonable Unknown 2.6 ELISA Recommend
18 India Jain 1994 Pregnant
women
xxs 252 Reasonable Unknown 3.6 RPHA n/c
19 India Choudhury 1995 Blood donors xxs 313 Good 19-52 2.2 ELISA 18.2 ELISA n/c
20 India Gill 1995 Pregnant women xxs 2000 Good <20-50 5 IA 12 ELISA Recommend
21 India Jain 1995 Blood donors xxs 3166 Good Unknown 1.8 NS n/c
22 India Reddy 1995 General pop xxs 91 Poor-Reason Unknown 4.4 ELISA 33 RIA n/c
23 India Thapa 1995 Children xxs 334 Good 3-15 1 ELISA n/c
24 India Kaur 1996 College students xxs 818 Reasonable 16-32 2.9 NS n/c
25 India Mittal 1996 Pregnant women xxs 850 Reasonable 16-38 4.6 RPHA 18 RPHA n/c
25 India Mittal 1996 Pregnant women xxs 850 Reasonable 16-38 6.3 ELISA n/c
26 India Sharma 1996 Newborns xxs 157 Good <1 5 RPHA n/c
26 India Sharma 1996 Pregnant women xxs 157 Good Unknown 10 RPHA n/c
27 India Nanu 1997 Blood donors xxs 132093 Good Unknown 1.9 ELISA n/c
28 India Sriprakash 1997 Pregnant women xxs 520 Reas-Good Unknown 4.6 ELISA n/c
29 India Prakash 1998 Pregnant women xxs 1112 Good Unknown 9.5 ELISA 12 ELISA Recommend
30 India Chowdhury 1999 General pop xxs 960 Good 0-84 5.3 EIA 13 EIA n/c
31 India Mohite 1999 Patients xxs 170 Poor Unknown 7.7 ELISA Concurrent
31 India Mohite 1999 Hospital employees xxs 166 Poor Unknown 1.9 ELISA Concurrent
31 India Mohite 1999 Blood donors xxs 1042 Poor Unknown 2.1 ELISA Concurrent
32 India Chandrase-
karan
2000 Blood donors xxs 1819 Reasonable Unknown 4 ELISA n/c
32 India Chandrase-
karan
2000 Hospital staff xxs 75 Reasonable Unknown 5.3 ELISA n/c
33 India Murhekar 2000 Nicobarese tribal pop xxs 1144 Good 5-80 23.3 ELISA Recommend
33 India Murhekar 2000 Shompens tribal pop xxs 37 Good Unknown 37.8 ELISA Recommend
33 India Murhekar 2000 Onges tribal pop xxs 58 Good Unknown 31.0 ELISA Recommend
33 India Murhekar 2000 Andamanese tribal pop xxs 27 Good Uknown 3.7 ELISA Recommend
34 India Singh 2000 General pop xxs 1553 Good 0-40+ 3.7 ELISA Recommend
35 India Ahmad 2001 Adults xxs 946 Poor-Reason Unknown 2.4 ELISA Prior
36 India Kalaivani 2001 General tribal pop xxs 161 Good 0-90 1.9 ELISA n/c
37 India Thakur 2002 Family contacts of
chronic liver
disease patients
xxs 373 Reasonable 1-50+ 17.4 IA n/c
38 India Risbud 2002 STD clinic attendees xxs 497 Poor <20-30+ 3.6 ELISA 43.2 ELISA Recommend
39 India Murhekar 2003 Jarawas tribal pop xxs 64 Reasonable 5+ 65.6 ELISA 68.8 ELISA Recommend
40 India Murhekar 2004 Children in Andaman
and Nicobar Islands
xxs 1574 Good 5-14+ 22.5 ELISA Recommend
41 India Qamer 2004 Pediatric patients xxs 460 Poor-Reason 0-14 4.35 ELISA n/c
42 India Shenoy 2004 Pregnant women xxs 300 Poor-Reason Unknown 4.0 ELISA 8.33 ELISA n/c
43 India Singh 2004 Blood donors xxs 128589 Reasonable Unknown 1.8 ELISA n/c
44 India Chowdhury 2005 General pop xxs 7653 Good <10-60+ 2.97 EIA n/c
45 India Kurien 2005 Tamil Nadu general pop xxs 1981 Good 15-45 5.7 ELISA 23.5 ELISA n/c
46 India Gupta 2006 HIV positive patients xxs 451 Poor-Reason 5-70 5.3 ELISA n/c
46 India Gupta 2006 Blood donors xxs 428 Poor-Reason 16-67 1.4 ELISA n/c
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47 India Sandesh 2006 Blood donors xxs 64823 Good Unknown 0.71 ELISA n/c
47 India Sandesh 2006 Pregnant women xxs 70659 Good Unknown 0.25 ELISA n/c
48 India Bhattacharya 2007 Blood donors (2004) xxs 113051 Good Unknown 1.3 ELISA n/c
48 India Bhattacharya 2007 Blood donors (2005) xxs 106695 Good Unknown 1.7 ELISA n/c
49 India Biswas 2007 Idu Mishmi tribal pop xxs 438 Good 2-57 21.2 ELISA 36.6 ELISA 92.3 ELISA n/c
50 India Carey 2007 Adults seeking
treatment for a
mental disorder
xxs 948 Poor 18-48+ 3.0 ELISA n/c
51 India Pahuja 2007 Blood donors xxs 28956 Good 18-60 2.2 ELISA Recommend
52 India Rai 2007 HIV positive patients xxs 58 Poor Unknown 1.7 NS 17.2 NS n/c
53 India Tripathi 2007 HIV positive patients xxs 620 Good 25-50 2.25 ELISA n/c
54 India Behal 2008 General pop xxs 20000 Good 19-55 2.25 ELISA Concurrent
55 India Jindal 2008 Injection drug users xxs 157 Reasonable Unknown 17.8 ELISA Recommend
55 India Jindal 2008 Truckers xxs 100 Reasonable Unknown 6.0 ELISA Recommend
55 India Jindal 2008 STD clinic patients xxs 350 Reasonable Unknown 3.7 ELISA Recommend
56 India Mahajan 2008 HIV patients xxs 230 Poor-Reason Unknown 3.5 ELISA n/c
57 India Saravanan 2008 Chronic liver
disease patients
xxs 69 Poor 40-65 57 ELISA 26 ELISA n/c
58 India Chatterjee 2009 Pregnant women xxs 36379 Good Unknown 0.8 ELISA Recommend
59 Myanmar Nakai 2001 General blood donors xxs 213 Reasonable 7-80 8 NS n/c
60 Nepal Shrestha 1990 General pop xxs 2555 Reasonable 0-41+ .9 RPHA 43.5 EIA n/c
61 Nepal Rai 1994 General pop xxs 303 Poor Unknown 0 RPHA n/c
62 Nepal Nakashima 1995 Adults xxs 676 Good 15-84 .3 RPHA 7.7 RIA n/c
63 Nepal Manandhar 1998 General male pop xxs 478 Reasonable 13-71 3.8 ELISA n/c
64 Nepal Sawayama 1999 Adults xxs 458 Reasonable 15-90 1.1 PHA 7.2 RIA Recommend
65 Nepal Joshi 2003 Adult males xxs 627 Reasonable 17-48 2.7 IC Recommend
66 Nepal Srestha 2007 Patients with liver
cirrhosis or
hepatocellular carcinoma
xxs 121 Reasonable 23-83 40 PHA 70 RIA n/c
WHO WPR-A Region
1 Australia Gill 1990 School children xxs 607 Reasonable 4-19 .03 EIA Prior
2 Australia Gardner 1992 School children xxs 1104 Good 9-17 .36 EIA Recommend
3 Australia Burgess 1993 School children xxs 2883 Good 11-12 .02 RIA 67 RIA 5.9 RIA Recommend
4 Australia Patterson 1993 General pop xxs 422 Good Unknown 0 1 RIA Recommend
4 Australia Patterson 1993 Aborigines xxs 310 Good Unknown 6.1 RIA 15.8 RIA 29.7 RIA Recommend
5 Australia Oman 1997 Pregnant women xxs 63695 Good Unknown .52 NS Recommend
6 Australia Gibney 2008 Sub-Saharan African
immigrants
xxs 383 Reasonable 16-75 22 IA 20 IA 68 IA Recommend
7 Australia Schultz 2008 Infant pop in northern
territory
xxs 973 Reasonable Newborn 3.7 NS n/c
8 Brunei Alexander 1990 General pop xxs 22828 Reasonable Unknown 6.1 EIA n/c
9 Brunei Sebastian 1990 Pregnant women xxs 1267 Reasonable 11-50 3.2 ELISA n/c
10 Japan Hayashi 1990 Children xxs 1529 Reasonable 1-4 .1 RPHA Concurrent
11 Japane Sakugawa 1990 General pop xxs 2231 Reasonable 5-80+ 6.3 RPHA 5.7 RIA Recommend
12 Japan Ochi 1991 General pop xxs 579 Reas-Good 9-84 11 RIA n/c
13 Japan Akbar 1992 General pop xxs 1118 Reasonable 4-90 .4 RPHA, PHA, and ELISA Concurrent
14 Japan Maeda 1992 Adults males xxs 122165 Good 16-64 1 RPHA n/c
14 Japan Maeda 1992 Adult females xxs 107248 Good 16-64 .7 RPHA n/c
15 Japan Koyama 1997 Adults xxs 5152 Reas-Good > 35 .9 PHA n/c
16 Japan Furusyo 1998 General pop xxs 521 Reasonable 0-60+ 4.4 RPHA 41.1 RIA n/c
17 Japan Hokama 1998 Pregnant women xxs 2227 Good Unknown 1.1 NS Post
18 Japan Sata 1998 Adults xxs 509 Good 20-94 2.6 EIA 46 EIA n/c
19 Japan Furusyo 2000 General pop xxs 298 Poor-Reason 3-90 29.2 RIA n/c
20 Japan Fujiwara 2003 Atomic bomb survivors xxs 6121 Poor <50-70+ 1.8 PHA n/c
21 Japan Toyoda 2004 Hemophilia patients xxs 43 Poor Unknown 86 EIA n/c
22 Japan Koike 2008 HIV positive patients xxs 5998 Poor Unknown 6.4 NS n/c
23 Japan Nagao 2008 Dental care workers xxs 141 Poor 29-80+ 12.1 CLIA Recommend
24 New Zealand Welch 1990 Children xxs 432 Reasonable 14-16 0 EIA 1.7 EIA Prior
25 New Zealand Chapman 2000 Adults xxs 1064 Good Unknown .3 ELISA .66 ELISA n/c
26 New Zealand Robinson 2005 General pop xxs 177328 Poor-Reason Unknown 5.7 NS Recommend
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Appendix B (Continued )
Country Source Source
Year
Population studied Study
designa
Sample
size
Study quality Age range HBsAg
preva-
lence (%)
Testing
Method
Used
HBeAg
preva-
lenceb (%)
Testing
Method
Used
Anti-HBc
preva-
lencec (%)
Testing
Method
Used
Vaccination
Interventiond
WHO WPR-B Region
1 American Samoa Mahoney 1993 Children xxs 95 Good 3-4 0 NS 2 NS Post
1 American Samoa Mahoney 1993 Children xxs 386 Good 6-11 2 NS 13.7 NS Post
2 Cambodia Thuring 1993 Adults xxs 305 Reasonable 15-60 8 NS 61 17 Recommend
2 Cambodia Thuring 1993 Children xxs 200 Poor 0-15 9 NS 4 Recommend
3 Chinae Xiao 1990 Pop of Hunan
Province
xxs 3089 Good 1-60+ 17.87 ELISA 48.02 ELISA 73.03 ELISA n/c
4 China Seiji 1991 Adults xxs 968 Good 15-60 3.7 RIA 37.7 RIA n/c
5 China Seiji 1991 Adults xxs 1075 Reas-Good 16-60 8.2 RIA 53.6 RIA n/c
6 China (Taiwan) Tsai 1991 Blood donors xxs 1135 Reasonable 18-60 4.5 EIA n/c
7 China (Taiwan) Tsen 1991 Children xxs 1134 Reas-Good 0-15 4.8 RIA 14.8 RIA Post
7 China (Taiwan) Tsen 1991 Children xxs 400 Reas-Good < 5 2.0 RIA 7.4 RIA Post
8 Chinae Fen 1992 Pop of Xiyang xxs 471 Reasonable 0-50 10.19 ELISA 19.11 ELISA n/c
9 Chinae Luo 1992 Pop of Guandong xxs 2233 Reasonable 0-96 10.6 ELISA 24.8 ELISA n/c
10 China Tao 1992 General pop xxs 438 Reas-Good 1-60+ 2.5 RPHA n/c
11 Chinae Luo 1993 General pop xxs 2042 Reasonable Unknown 14.35 RIA 24.19 RIA n/c
12 China (Taiwan) Wang 1993 Adolescents xxs 875 Good 13-16 18.9 EIA Recommend
13 China (Taiwan) Lin 1994 Pregnant women xxs 11814 Good 21-40 12.5 EIA 37 EIA n/c
14 China (Hong Kong) Marshall 1995 University students xxs 3569 Reas-Good Unknown 3.6 NS Prior
15 China (Taiwan) Chen 1996 Children xxs 1515 Good < 12 1.3 RIA 4.0 RIA Post
16 China Wu 1996 General pop xxs 1591 Good 1-59 6.3 EIA 35.6 EIA n/c
17 China (Hong Kong) Kwan 1997 Pregnant women xxs 2480 Good 16-44 10 NS Concurrent
18 China (Hong Kong) Chan 2002 Patients with
cryptogenic liver
cirrhosis
xxs 28 Poor Unknown 17.9 EIA n/c
18 China (Hong Kong) Chan 2002 General pop xxs 49 Poor Unknown 10.2 EIA n/c
19 Chinae Lin 1997 Children cos 2027 Reasonable 1-16 2.22 RIA 7.82 RIA Post
20 China Shimbo 1997 Urban female pop xxs 50 Poor-Reason 21-55 10 EIA 42 RIA n/c
20 China Shimbo 1997 Rural female pop xxs 50 Poor-Reason 21-55 6 EIA 54 RIA n/c
21 Chinae Li 1998 General pop xxs 3809 Good 1-59 17.25 RIA 8.42 EIA 68.58 RIA Recommend
22 China Shimbo 1998 Urban female pop xxs 50 Poor-Reason 21-55 2 EIA 48 RIA n/c
22 China Shimbo 1998 Rural female pop xxs 99 Poor-Reason 21-55 8 EIA 63 RIA n/c
23 China Zhang 1998 Urban college students xxs 1557 Good 17-22 6.3 ELISA n/c
23 China Zhang 1998 Rural college students xxs 1368 Good 17-22 10.8 ELISA n/c
24 China (Taiwan) Hsu 1999 Children xxs 1500 Good 6 1.7 RIA Post
25 China (Taiwan) Wang 1999 Adults xxs 459 Poor-Reason > 20 32.6 IA n/c
26 China (Taiwan) Dai 2000 Adults xxs 200 Poor-Reason 22-79 28 ELISA n/c
27 China (Taiwan) Lin 2000 Aboriginal pop xxs 1680 Good 0-70+ 14.8 EIA n/c
28 China Qu 2000 Females xxs 494 Reasonable 20-62 8.1 RIA 55 RIA n/c
29 China Zhang 2000 Urban female pop xxs 50 Reasonable 25-58 12 EIA 46 RIA n/c
29 China Zhang 2000 Rural female pop xxs 50 Reasonable 21-61 6 EIA 44 RIA n/c
30 China (Taiwan) Wang 2002 Pop of A-Lien xxs 6095 Poor 35+ 13.8 EIA n/c
31 China (Taiwan) Lin 2003 Pregnant women xxs 43076 Good Unknown 12.0 RIA 29.5 RIA n/c
32 Chinac Wang 2006 Injection drug users xxs 2025 Poor-Reason Unknown 14.5 ELISA n/c
33 China (Taiwan) Chang 2007 College freshmen born
after July 1, 1984
xxs 1204 Good 21-54 7.4 MEIA 23.5 MEIA Post
33 China (Taiwan) Chang 2007 College freshmen born
before July 1, 1984
xxs 6388 Good 16-20 2.2 MEIA 6.7 MEIA Post
34 China (Taiwan) Huang 2007 Immunized children xxs 2451 Poor-Reason 3-15 3.8 RIA Post
35 China (Taiwan) Lin 2007 Male IV drug users xxs 1655 Poor-Reason 20-67 22.2 RIA n/c
36 China Ma 2007 Men who have sex
with men
xxs 1292 Poor-Reason 16+ 8.2 ELISA n/c
37 China Hsing 2008 Biliary tract cancer
patients
xxs 417 Reasonable Unknown 9.8 EIA 77.5 ELISA n/c
37 China Hsing 2008 Biliary stones patients xxs 517 Reasonable Unknown 9.7 EIA 71.1 ELISA n/c
37 China Hsing 2008 Healthy controls xxs 762 Reasonable Unknown 7.3 EIA 73.8 ELISA n/c
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38 China (Taiwan) Lin 2008 Pregnant Cambodian
women
xxs 42 Poor-Reason Unknown 9.5 MEIA Concurrent
38 China (Taiwan) Lin 2008 Pregnant Filipino
women
xxs 71 Poor-Reason Unknown 9.9 MEIA Concurrent
38 China (Taiwan) Lin 2008 Pregnant Indonesian
women
xxs 171 Poor-Reason Unknown 8.8 MEIA Concurrent
38 China (Taiwan) Lin 2008 Pregnant Taiwanese
women
xxs 10327 Poor-Reason Unknown 15.5 MEIA Concurrent
38 China (Taiwan) Lin 2008 Pregnant Thai women xxs 20 Poor-Reason Unknown 5.0 MEIA Concurrent
38 China (Taiwan) Lin 2008 Pregnant Vietnamese
women
xxs 1114 Poor-Reason Unknown 8.9 MEIA Concurrent
39 Chinac Qian 2008 General pop xxs 3744 Reas-Good Unknown 4.5 ELISA 51.4 ELISA Post
40 China (Taiwan) Chu 2009 Male non-injection
drug users in detox
xxs 561 Good 16-57 16.9 MEIA Post
40 China (Taiwan) Chu 2009 Male injection drug
users in detox
xxs 192 Good 19-55 16.7 MEIA Post
41 China Fang 2009 General pop xxs 359 Poor-Reason 15-82 11.7 ELISA Recommend
41 China Fang 2009 Cryptogenic chronic
liver disease patients
xxs 159 Poor-Reason 25-74 47.2 ELISA Recommend
41 China Fang 2009 Hepatocellular
carcinoma patients
xxs 135 Poor-Reason 35-70 72.6 ELISA Recommend
42 China (Taiwan) Mu 2009 Vaccinated, HBsAg
negative children
xxs 43 Poor-Reason 1-12 6.5 ELISA n/c
43 Fiji Wilson 2000 Immunized pre-school
children
xxs 326429 Good 1-2 .7 NS 77.0 NS Post
43 Fiji Wilson 2000 Mothers of immunized
children
xxs 292273 Good Unknown 6.6 NS 70.6 NS 57.9 NS Post
43 Fiji Wilson 2000 Unimmunized students xxs 294029 Good 10-13 6.9 NS 39.9 NS Post
44 French Polynesia Boutin 1990 General pop xxs 957 Good 0-60+ 10.5 ELISA 19.3 ELISA Prior
43 Kiribati Wilson 2000 Immunized pre-school
children
xxs 216078 Good 1-2 3.8 NS 12.8 NS Post
43 Kiribati Wilson 2000 Mothers of pre-school
children
xxs 179993 Good Unknown 15.1 NS 47.8 NS 89.4 NS Post
43 Kiribati Wilson 2000 Unimmunized children xxs 135529 Good 10-13 27.4 NS 92.6 NS Prior
44 Mongolia Fujioka 1998 Outpatients xxs 150 Reasonable Unknown 29 CIA n/c
45 Mongolia Tsatsralt-Od 2005 Blood donors xxs 403 Poor-Reason 18-66 7.4 RPHA 26.7 EIA 66.7 PHA n/c
46 Mongolia Davaalkham 2007 General children pop xxs 1145 Good 7-12 5.2 CLIA 15.6 CLIA Post
47 Mongolia Tsatsralt-Od 2007 General children pop xxs 655 Poor-Reason 0-15 7.2 ELISA 19.1 PHA Recommend
48 Papua New Guinea Sapuri 1991 Newborns xxs 100 Poor-Reason <1 5 RPHA Recommend
48 Papua New Guinea Sapuri 1991 Pregnant women xxs 100 Poor-Reason Unknown 11 RPHA Recommend
49 Papua New Guinea Spooner 1990 Pregnant women xxs 146 Reas-Good 16-38 14 EIA 32 EIA Recommend
50 Papua New Guinea Sanders 1992 Females xxs 106 Poor 20-50 36.8 EIA 17.9 EIA 0 EIA Post
50 Papua New Guinea Sanders 1992 Children xxs 56 Poor 6-18 46 EIA 65 EIA 0 EIA Post
51 Papua New Guinea Nemba 1993 Newborns xxs 50 Good < 1 4 RPHA Recommend
51 Papua New Guinea Nemba 1993 Children xxs 415 Good 0-4 16.7 RPHA Recommend
52 Papua New Guinea Yamaguchi 1993 Adults xxs 723 Reasonable 18-65 11.9 ELISA & RPHA n/c
53 Philippines Arguillas 1991 Blood donors xxs 392 Reasonable 18-58 2.2 RPHA n/c
53 Philippines Arguillas 1991 Medical personnel xxs 123 Reasonable 20-53 6.5 RPHA n/c
54 Philippines Richards 1996 Pregnant women xxs 502 Reasonable 19-43 5.6 RIA 25 RIA Recommend
55 Philippines Subida 1997 Females xxs 50 Poor 21-59 0 EIA 0 EIA 4 RIA n/c
56 Solomon Islands Furusyo 1999 Outpatients and
blood donors
xxs 1610 Reasonable 0-80 19.6 EIA 41.3 RIA 79.4 RIA n/c
57 Solomon Islands Lucas 1999 Blood donors xxs 598 Reasonable Unknown 25.1 NS 84.4 NS n/c
58 Solomon Islands Utsumi 2007 Melanesian and
Micronesian general pop
xxs 564 Poor-Reason 18-60+ 21.5 RPHA 21.5 EIA n/c
59 South Korea Kim 2007 Patients with normal
serum ALT levels
xxs 195 Poor 15-94 51 MEIA n/c
60 South Korea Park 2008 B-cell non-hodgkin’s
lymphoma patients
xxs 235 Reasonable 2-82 14 ELISA n/c
60 South Korea Park 2008 Hospital matched
controls
xxs 235 Reasonable 20-88 8.1 ELISA n/c
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Appendix B (Continued )
Country Source Source
Year
Population studied Study
designa
Sample
size
Study quality Age range HBsAg
preva-
lence (%)
Testing
Method
Used
HBeAg
preva-
lenceb (%)
Testing
Method
Used
Anti-HBc
preva-
lencec (%)
Testing
Method
Used
Vaccination
Interventiond
61 South Korea Song 2009 General pop xxs 1091 Poor-Reason Unknown 4.0 NS 39.3 NS n/c
43 Tonga Wilson 2000 Immunized pre-
school children
xxs 216078 Good 1-2 3.8 NS 12.3 NS Post
43 Tonga Wilson 2000 Mothers of immunized
children
xxs 216209 Good Unknown 18.6 NS 47.5 NS 84.7 NS Post
43 Tonga Wilson 2000 Unimmunized
children
xxs 227252 Good 10-13 11.1 NS 45 NS Post
62 Vanuatu Maher 1991 Children-group A xxs 112 Good 1-1.5 17 EIA 73.7 EIA Recommend
62 Vanuatu Maher 1991 Mothers of group
A children
xxs 110 Reas-Good Unknown 24.5 EIA 48.1 EIA Recommend
62 Vanuatu Maher 1991 Children- group B xxs 176 Good 2.5-3.5 30.1 EIA 84.9 EIA Recommend
62 Vanuatu Maher 1991 Children- group C xxs 194 Good 4.5-9.5 29.9 EIA 79.3 EIA Recommend
43 Vanuatu Wilson 2000 Immunized pre-school
children
xxs 137733 Good 1-2 3.0 NS 9.3 NS Post
43 Vanuatu Wilson 2000 Mothers of immunized
children
xxs 131138 Good Unknown 12.3 NS 50 NS 65.4 NS Post
43 Vanuatu Wilson 2000 Unimmunized students xxs 135797 Good 10-13 16.3 NS 54.1 NS Post
63 Viet Nam Tran 1993 Adults- Blood donors xxs 32300 Reasonable 17-50 9.5 ELISA n/c
63 Viet Nam Tran 1993 Pregnant women xxs 1000 Reasonable 18-41 9.9 ELISA n/c
64 Viet Nam Nakata 1994 General pop xxs 1343 Reasonable Unknown 13.3 PHA n/c
65 Viet Nam Song 1994 Blood donors from
Ho Chi Minh
xxs 491 Good Unknown 3.1 PHA n/c
65 Viet Nam Song 1994 Blood donors from
Hanoi
xxs 499 Good Unknown 3 PHA n/c
66 Viet Nam Katelaris 1995 Children xxs 87 Reasonable 2-12 19.5 EIA Recommend
67 Viet Nam Kakumu 1998 General pop xxs 890 Reas-Good 2-81 5.7 RPHA n/c
68 Viet Nam Barcus 2002 Severe malaria
patients
xxs 324 Reas-Good Unknown 23.8 ELISA n/c
Note: The number of population estimates of prevalence for the selected serological markers of Hepatitis B virus infection and immunity reﬂected in this table are: 736 for all ages, 81 for adults, 111 for blood/tissue donors, 110 for
pregnant women, 119 for children, 85 for patients, and 116 for other populations; 687 involving HBsAg seroprevalence estimates, 327 involving Anti-HBc, and 107 involving HBeAg.
a Study design abbreviation are as follows: xxs stands for cross sectional study, ccs stands for case-control study, and cos stands for cohort study.
b HBeAg prevalence is restricted to HBsAg positive individuals.
c Anti-HBc prevalence is based on persons with positive Anti-HBc in the total sample.
d For the purpose of this paper, vaccination intervention was categorized into the following ﬁve areas: 1) n/c, meaning no comment was made about vaccination interventions in the article, 2) Prior, meaning the purpose of the
study was to establish baseline data for a vaccination intervention, 3) Post, meaning the purpose of the study was to evaluate a vaccination intervention, 4) Recommend, meaning the article recommended that vaccination
interventions should be a priority based on study results, and 5) Concurrent, meaning that study results were partially attributed to ongoing vaccination interventions.
e Non-English papers.
Testing Method abbreviations are as follows: CIA- counting immunoassay; CIEP- counterimmunoelectrophoresis technique; CLIA – Chemiluminescent immunoassay; EIA- enzyme immunoassay; ELISA- enzyme linked
immunosorbent assay; HI- hemagglutination inhibition; IA- immunoenzymatic assay; IC – immunochomatography assay LATEX- latex agglutination; MEIA- microparticle enzyme immunoassay; MELISA- microelisa NS- not
speciﬁed or not available; PA- particle agglutination; PHA- passive hemagglutination; RPHA- reverse passive hemagglutination; RIA- radioimmunoassay.
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Figure 1. Median seroprevalence of HBsAg (%) among selected groups.
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Figure 2. Median seroprevalence of HBsAg (%) among special populations.
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Figure 3. Median seroprevalence of HBsAg (%) in patients.
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Figure 4. Median seroprevalence of HBeAg (%) for studies conducted within the WHO sub-region WPR-B.
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